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1   Introduction 
Plant sterols (phytosterols) are natural compounds from plants, found in low concentration in 
blood and tissues of humans. There exists a wide variety of phytosterol structures, but the most 
frequent phytosterols in nature are sitosterol, campesterol and stigmasterol. The major plant sterol 
is sitosterol (approximately 80%).  These compounds are not synthesized in the human body, but 
rather are derived entirely from the diet. The average Western diet contains between 160 to 360 
mg/day of both sitosterol and campesterol and 20 to 50 mg/day of sitostanol (1). 
Phytosterols are structurally similar to cholesterol except for substitutions at the C24 position of 
the side chain. Compared with cholesterol, campesterol has a methyl group at the C24 position of 
the side chain, whereas sitosterol has an additional ethyl group. Stigmasterol differs from 
sitosterol because of its additional double bond at the C22 position. Saturation of the delta 5 
double bond of campesterol and sitosterol leads to the formation of campestanol and sitostanol, 
respectively. 
 
Cholesterol and plant sterols can be oxidized to produce oxycholesterols and oxyphytosterols, 
respectively. Several oxidation products of cholesterol possess a number of biological effects and 
have been implicated in the etiology of atherosclerosis and cytotoxicity (2). Because of the 
structural similarity between plant sterols and cholesterol, analogous oxidation products might be 
formed by oxidation of the plant sterols. Thus, oxyphytosterols may have effects similar to those 
of oxycholesterols and therefore implications for human health.  
7-hydroperoxycholesterol and its degradation products 7α- and 7β- hydroxycholesterol and 
7-ketocholesterol have been found in LDL, whereas 7-hydroperoxycholesterol appears to be the 
most cytotoxic oxygenated lipid in LDL (3). An alternative pathway involved in the elimination 
of excess cholesterol involves side chain-oxidized oxycholesterol with an oxygen function at C27 
position by sterol 27-hydroxylase, due to its ability to pass cell membranes at a much faster rate 
than cholesterol (4).  
 
Sitosterolemia (also called phytosterolemia) is a rare autosomal recessively inherited disease. 
Only 40 patients have been identified worldwide so far (5). The disease is characterized by the 
accumulation of plant sterols and 5α-saturated stanols in plasma and tissues and clinically by 
tendon xanthomatosis and premature coronary artery atherosclerosis. The major biochemical 
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feature of sitosterolemia is hyperabsorption of sterols and reduction of biliary excretion of sterols 
(6). Since sitosterol is usually most abundant plant sterol in the diet, the disease has been named 
sitosterolemia. 
 
In most Western countries, atherosclerosis is the leading cause of death. In the United States 
alone, it causes almost one million deaths every year, twice as many as from cancer (7). Despite 
significant medical advances, coronary artery disease and atherosclerotic stroke are responsible 
for more deaths than all other causes combined. The risk of premature atherosclerosis was 
observed in several subjects with sitosterolemia who died due to acute myocardial infarctions 
caused by extensive coronary and aortic atherosclerosis (8). 
 
Recently, it was found that oxyphytosterols are present in elevated concentration in serum from 
sitosterolemic patients, while the concentration of serum oxyphytosterols in healthy control 
subjects was below the limit of detection (9). However, the biological effects of phytosterol 
oxidation products are not well known. Patients with sitosterolemia hyperabsorb and retain all 
sterols, including plant sterols and shellfish sterols. This is caused by mutations in one of the two 
tandem ATP-binding cassette transporter (ABCG5 or ABCG8) genes. These ABC transporters 
pump plant sterols out of the mucosa cells into the gut lumen and out of the liver into bile; 
therefore mutations in these transporters, resulting in hyperabsorption and diminished biliary 
excretion of plant sterols, is followed by markedly elevated concentrations of plant sterols in 
serum (10). 
 
A low-sterol diet is one treatment option intended to reduce high plasma sterol levels in 
sitosterolemic patients. These dietary changes are, however, not very efficient. Bile acid binding 
resins (e.g. cholestyramine) or ileal bypass operations can effectively reduce the plasma sterol 
concentrations and the xanthomas (6) in patients with sitosterolemia. 
HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, atorvastatin and fluvastatin), 
which are widely used in the treatment of hypercholesterolemia, have also been tried in treatment 
of patients with sitosterolemia, but were not effective. 
Ezetimibe is the first agent in a new class of drugs known as selective cholesterol absorption 
inhibitors, which have been found to be useful for lowering total cholesterol and low density 
lipoprotein levels (11). Research examining the effect of ezetimibe on serum plant sterol 
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concentrations in sitosterolemic patients found that ezetimibe produces significant and 
progressive reductions in the plant sterol levels in those patients (12). 
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2   Aim of the study 
Sitosterolemia is a very rare inherited disease characterized biochemically by increased serum 
levels of plant sterols and stanols and clinically by premature coronary artery artheriosclerosis 
and xanthomatos. This disease can be treated by illeal pass operation, by using bile acids binding 
resins like cholestyramine or, more recently, by treatment with ezetimibe, the first agent in the 
new class of drugs called cholesterol absorption inhibitors. 
Several oxidation products of cholesterol have been implicated in the etiology of atherosclerosis 
and cytotoxicity. Because plant sterols are structurally similar to cholesterol, oxidation products 
corresponding to the oxycholesterols might be formed by oxidation. Whether these oxidized 
compounds of plant sterols have biological or pathological effects (as has been suggested for 
oxycholesterols) is still unknown. 
 
The aim of the present two studies can be explained as follows: 
The first study examined whether oxidized plant sterols and oxycholesterols could be identified 
in human serum of sitosterolemic patients and in two frequently used soy-based lipid emulsions. 
Since ezetimibe reduces not only cholesterol absorption (11) but also serum plant sterol 
concentrations (12), we investigated whether ezetimibe also reduces serum concentration of 
oxycholesterols and oxyphytosterols in sitosterolemic patients during different drug treatments. 
In addition, serum samples from patients receiving intravenous infusions of lipid emulsion were 
analyzed for the presence of oxycholesterols and oxyphytosterols. 
The aim of the second study was to investigate which drug could best be used in the treatment of 
sitosterolemia before ezetimibe was available. 
To pursue these investigations, we employed a sensitive gas chromatography-mass spectrometry 
method for the first study, using deuterium labelled for oxycholesterols and oxyphytosterols as 
internal standards, whereas in the second study we used a gas chromatography method with  
5α-cholestane as an internal standard.
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3   General background  
3.1  Cholesterol                                                     
Cholesterol is an extremely important biological molecule that plays a central role in the 
membrane of cells, as well as being a precursor for the synthesis of a number of equally 
important steroids,  including bile acids, adrenocortical hormones, sex hormones, and vitamin  D. 
Like all steroids, the cholesterol molecule consists of two parts, a nucleus and a side chain. The 
nucleus is based on phenanthrene (rings A, B, and C) to which a cyclopentane ring (D) is 
attached (Figure 1). 
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                                          Figure 1 The chemical structure of cholesterol  
 
3.1.1  Cholesterol absorption 
The human body fulfills its requirement for cholesterol in two ways:  it is synthesized in the body 
itself (mainly in the liver) and it is absorbed through the intestine during digestion of foods from 
animal sources (including egg yolks, meat and whole milk products) (13). Cholesterol and plant 
sterols are insoluble in the aqueous environment of the intestine. The solubilization of dietary 
sterols takes place in micelles containing conjugated bile acids, hydrolytic products of 
triglycerides, lecithin and fatty acids (14). The molecular mechanism of the dietary cholesterol 
absorption process from the intestine is only poorly understood. Dietary cholesterol, which is 
mostly unesterified, is solubilized in micelles and reaches the intestinal mucosa, where it passes 
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through the brush border. It is partially esterified by intestinal acyl CoA: cholesterol 
acyltransferase (ACAT) packaged into chylomicrons (CM) and secreted into the lymphatic 
system. As chylomicrons circulate, the core triglycerides are hydrolyzed by lipoprotein lipase, 
resulting in the formation of chylomicron remnants, which are rapidly removed by the liver 
(Figure 2) (15).   
More recently, Altmann et al. (16) identified Niemann-Pick C1 Like1 (NPC1L1) as a critical 
protein (expressed at the apical surface of enterocytes) involved in the intestinal absorption of 
both dietary and biliary cholesterol. Furthermore, adenosine triphosphate (ATP)-binding cassette 
(ABC) transporters ABCG5 and ABCG8 represent apical sterol export pumps that promote active 
efflux of cholesterol and plant sterols from enterocytes back into the intestinal lumen for 
excretion. This provides an explantion why cholesterol absorption is a selective process, with 
plant sterols and other noncholesterol sterols being absorbed poorly. The ABCG5 and ABCG8  
transporters are also expressed at the level of the canalicular membrane in the liver. They work as 
efflux pumps and transport free sterols into the bile, thereby regulating the absorption as well as 
the biliary secretion of cholesterol and plant sterols (15, 17). This explains the increase in 
intestinal sterol absorption and decrease in biliary sterol elimination in patients with 
sitosterolemia. 
 
                                                 
      
                                                  Figure 2 Cholesterol intestinal absorption (15) 
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3.1.2  Cholesterol biosynthesis 
Cholesterol synthesis occurs in the cytoplasm and microsomes from the two-carbon acetate 
groups of acetyl-CoA. The acetyl-CoA utilized for cholesterol biosynthesis is derived from an 
oxidation reaction (e.g. fatty acids or pyruvate) in the mitochondria and is transported to the 
cytoplasm. All reduction reactions of cholesterol biosynthesis use NADPH as a cofactor. Acetyl 
CoA units are converted to mevalonate by a series of reactions that begins with the formation of 
HMG-CoA. Two moles of acetyl-CoA are condensed in a reversal of the thiolase reaction, 
forming acetoacetyl-CoA. Acetoacetyl-CoA and a third mole of acetyl-CoA are converted to 
HMG-CoA by the action of HMG-CoA synthetase. HMG-CoA is converted to mevalonate by 
HMG-CoA reductase (HMG-CoAR). HMG-CoAR absolutely requires NADPH as a cofactor and 
two moles of NADPH are consumed during the conversion of HMG-CoA to mevalonate. The 
reaction catalyzed by HMG-CoAR is the rate limiting step of cholesterol biosynthesis (Figure 3). 
         
                Acetyl-CoA                                                     2 NADPH 
                       +                                 HMG-CoA                                         mevalonate 
             Acetoacetyl-CoA                                          HMG-CoA reductase 
 
                                                                                                                    -CO2    3ATP 
                                                                                                                     
 
                                                                                                                      isopentenyl 
                                                                                                                   pyrophosphate 
 
 
                                                                                
 
 
                                                                                                              geranyl pyrophosphate 
 
 
 
 
                                                                                                             farnesyl pyrophosphate 
          bile acids            steroids 
 
 
                 cholesterol                                     lanosterol                                  squalene 
 
                                                                                                   
                                                   Figure 3  Cholesterol biosynthesis  
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3.1.3  Cholesterol distribution 
Intestinal cholesterol and triglycerides are packaged with apolipoproteins in enterocytes of the 
small intestine to be secreted into the lymphatic system as chylomicrons. Intestinal cholesterol 
has four possible fates once it reaches the liver: it can be esterified and stored as cholesteryl esters 
in hepatocytes, packaged into very low density lipoprotein (VLDL) particles and secreted into the 
plasma, secreted into the bile, or converted into bile acids and secreted into the bile (18). 
Cholesterol in the blood is transported to and from cells by lipid-protein complexes called 
lipoproteins. They are of several kinds: Chylomicrons, intermediate lipoproteins (IDL), very low 
density lipoproteins (VLDL), low densitiy lipoproteins (LDL) and high density lipoproteins 
(HDL), Approximately 70% of circulating cholesterol is transported in LDL (18,19). These lipid-
protein complexes contain triglycerid droplets and cholesterol esters surrounded by polar 
phospholipids and proteins identified as apolipoproteins.  
 
3.1.4  Low Density Lipoproteins (LDL) 
Cholesterol can be transported to extra-hepatic tissues by VLDL which, is synthesized in the 
liver. In the circulation VLDL is converted to LDL through the action of endothelial cell- 
associated lipoprotein lipase enzyme. The almost exclusive apolipoprotein of LDL is apoB-100. 
The cellular uptake of cholesterol from LDL occurs following the interaction of LDL with the 
LDL receptors (also called apoB-100/ apoE receptors). The LDL receptor is a polypeptide of 839 
amino acids that spans the plasma membrane. An extracellular domain is responsible for apoB-
100/apoE binding, once LDL binds to the receptor, complexes are rapidly endocytosed. ATP 
dependent proton pumps lower the pH in the endosomes which results in dissociation of LDL 
from the receptor. 
 
3.1.5  Cholesterol excretion  
Hepatic conversion of cholesterol to bile acids followed by biliary secretion and subsequent fecal 
loss is a major metabolic step for the elimination of cholesterol from the body (20) but the 
excretion of cholesterol in this form is insufficient to compensate an excess dietary intake of 
cholesterol. The most abundant bile acids in human bile are chenodeoxycholic acid and cholic 
acid (Figure 4), referred to as the primary bile acids. Within the intestine the primary bile acids 
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are converted to the secondary bile acids by bacteria to deoxycholate (from cholate) and 
lithocholate (from chenodeoxycholate). Both primary and secondary bile acids are reabsorbed by 
the intestine and delivered back to the liver via the portal circulation. However, the absorption of 
lithocholates acid is much less than of all other bile acids. 
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                                     Figure 4 The chemical structure of bile acids                                           
 
 
3.1.6  Cholesterol and atherosclerosis 
While cholesterol is an essential part of a healthy body, high level of cholesterol (in particular 
high level of LDL-C) in the blood known as hypercholesterolemia, is a well established risk 
factor for development of atherosclerosis and cardiovascular disease. 
During the last decade, several lines of evidence have suggested that oxidative modification of 
LDL plays a key role in this respect. Oxidation of LDL has been found to increase its uptake in 
macrophages leading to formation of macrophage foam cells which are the basis of fatty streaks, 
which are the first morphological stage of atherosclerosis (21). Other studies have indicated that 
oxidized LDL may induce vascular inflammation and even give rise to autoimmune reactions in 
the vascular wall (22). Familial hypercholesterolemia (FH) is the most common and most severe 
form of monogenic hypercholesterolemia. FH is caused by mutation in the LDL-R gene; patients 
with two mutated LDL-R alleles (FH homozygotes) are much more severely affected than those 
with one mutated allele (FH heterozygotes) (18). FH homozygotes develop cutaneous xanthomas 
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and coronary atherosclerosis in childhood (23).  Atherosclerosis is characterized by thickening of 
arterial walls through accumulation of lipids in the inner layers (intima) of the arteries. The 
development of atherosclerosis has been shown to be positively correlated to the level of 
cholesterol in plasma. Atherosclerotic plaques consist primarily of lipids such as cholesterol, 
cholesterol esters and phospholipids (24). The severity  of  atherosclerosis  is  proportional  to  
the  extent  and  duration  of  elevated  plasma LDL-C (25, 26).  
Some individuals with a clinical presentation similar to FH and reduced rates of LDL catabolism 
were found to have normal LDL-R activity. When LDL from these patients was infused into 
normocholesterolemic subjects, the heterologous LDL was cleared at a reduced rate compared 
with normal autologous LDL (27). The disease, familial defective apo B-100 (FDB) results from 
a missense mutation in the LDL-R- binding domain of apo B-100. 
Large scale clinical trials provide convincing evidence that substantial LDL lowering reduces 
cardiovascular morbidity and mortality, even in subjects who do not have elevated LDL-C levels 
(28, 29). 
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3.2  Oxycholesterols 
3.2.1  Formation and sources of oxycholesterols 
The oxygenation of cholesterol results in compounds known as oxycholesterols or cholesterol 
oxidation products (COPs), which can be defined as oxygenated derivatives of cholesterol that 
are intermediates or even end products in cholesterol excretion pathways. They may be formed 
directly by physical processes such as heating and radiation (30), by non-enzymatic processes 
involving reactive oxygen and free radical species or enzymatically by specific cytochrome P450 
(CYP450) monooxygenases (30, 31). 
 
7α-hydroxycholesterol, 7β-hydroxycholesterol, 7-ketocholesterol, 5α,6α-epoxycholesterol, 5β, 
6β-epoxycholesterol and 3β, 5α, 6β-trihydroxycholestane can be formed either by enzymatic 
pathways or by autoxidation at ring B (Figure 5). On the other hand, the side chain is mainly 
attacked by CYP450 specific enzymes, resulting in various hydroxy derivatives of cholesterol 
like 24S-hydroxycholesterol and 27- hydroxycholesterol (2, 4).  
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                             Figure 5  Autoxidation at ring B of the cholesterol nucleus 
 
While all cells may have at least some ability to oxygenate cholesterol, the liver and endocrine 
organs have the highest capacity for such reaction. The physical properties of oxycholesterols 
allow them to pass lipophilic membranes and to be redistributed in the cells at a much faster rate 
than cholesterol itself, resulting in rapid degradation and excretion (32). The major 
oxycholesterols in the circulation are transported by lipoproteins, and their distribution between 
different lipoprotein fractions is almost similar to that of cholesterol (33).   
According to in vitro studies, oxycholesterols play a number of important roles in cholesterol 
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turnover, atherosclerosis, apoptosis, necrosis, inflammation and development of gallstones (2, 
34). These studies also demonstrate the cytotoxic effects on the cultured endothelial cells and 
arterial smooth muscle cells, suggesting that oxycholesterols have an atherogenic role (4, 35). 
The structures of some important oxycholesterols are depicted in Figure 6.  
7-hydroperoxycholesterol seems to be the most cytotoxic oxygenated lipid present in oxidized 
LDL (36). This oxycholesterol is rapidly decomposed into 7α- and 7β-hydroxycholesterol and  
7-ketocholesterol which may be found in relatively high concentration in foam cells and fatty 
streaks. 
 
 
 
 
Figure 6 Primary cholesterol oxygenation reaction mediated by different cytochrom P-450 
species or occuring non-enzymatically in the presence of reactive oxygen species (ROS).  
25–hydroxycholesterol is formed by the enzyme cholesterol-25-hydroxylase (4). 
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Many oxycholesterols have been found in human tissue and fluids such as human plasma, brain, 
atherogenic lipoproteins and atherosclerotic plaque. How these oxycholesterols originate in vivo 
is not fully understood. Some researchers suggest that they come from dietary sources, while 
others believe that they may be generated by non-enzymatic oxidation (2). Dietary sources of 
oxycholesterols are cholesterol-rich foods, especially those products which are heated in the 
presence of oxygen or are stored for long periods. The most commonly detected oxycholesterols 
in foods are the major products of cholesterol autoxidation: 7-keto-, 7β-hydroxy-, 5,6α/β-epoxy-
cholesterol. The presence of dietary oxycholesterols in the circulation or in a specific tissue 
depends on the rate of absorption from the gut, transport to the specific tissue, and elimination of 
the COPs from the tissue by transport or metabolism. It has been shown that intestinal cholesterol 
absorption is mediated by NPC1L1 and the ATP-binding cassette tranporters ABCG5 and 
ABCG8, but it is yet not known whether these transporters are also involved in COPs absorption. 
 
3.2.2  Oxycholesterols and atherosclerosis 
It has been suggested, based on in vitro experiments, that cholesterol oxidation compounds are 
atherogenic, while oxycholesterols demonstrate cytotoxic effects on cultured endothelial cells. 
The highly nonphysiological conditions used in most experiments, however, preclude drawing 
strong conclusions. Numerous studies have been published about the effects of dietary 
oxycholesterols on experimental animals (2). Out of thirteen of these studies, six indicate a 
proatherogenic effect and four an antiatherogenic effect, while three show no significant effect. 
To date there is no direct evidence that dietary oxycholesterols contribute to atherosclerosis in 
humans (4). On the other hand, many studies have detected oxycholesterols in human 
atherosclerotic plaques (37, 38, 39), although relatively few have presented quantitative data (2). 
Oxidative modified LDL, which has proatherogenic effects, appears to be the most cytotoxic 
lipid. It contains 7-hydroperoxycholesterol and its degradation products 7α-hydroxycholesterol, 
7β-hydroxycholesterol and 7-ketocholesterol.  
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3.3  Phytosterols 
Plant sterols, also referred to as phytosterols, are non-nutritive compounds that have a chemical 
structure related to that of cholesterol. They differ in their side chain configuration only by an 
additional ethyl (β-sitosterol) or methyl (campesterol) group at the 24 carbon atom (39, 40) 
(Figure 7). Dehydrogenation of the carbon 22-23 bond of sitosterol leads to formation of 
stigmasterol, another common plant sterol. Phytostanols are saturated phytosterols where the 
delta 5 double bond is saturated and the hydrogen atom is positioned at the 5α position. 
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                                 Figure 7  The chemical structure of plant sterols            
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3.3.1  Metabolism of plant sterols 
Phytosterols are not endogenously synthesized in the body. In healthy humans, the absorption 
rate of plant sterols depends on their side chain length and is less than of cholesterol (41).   
Recent studies have indicated that plant sterols and stanols are taken up by the mucous cells 
almost to the same extent as cholesterol (42). However, they are rapidly resecreted into the 
intestinal lumen by the ABCG5 and/or ABCG8 co-transporters. The resecretion into the intestine 
may be due to the fact that the enzyme acyl CoA: cholesterol acyltransferase 2 (ACAT 2) does 
not esterify plant sterol. Research by Davis et al. indicates that NPC1L1 is important for the 
uptake of both cholesterol and structurally related phytosterols. The plasma levels of plant sterols 
were found to be undetectable in NPC1L1 null mice and were reduced by more than 90% 
compared to wild-type mice (43). 
 
Intestinal phytosterol absorption is a selective process, with campesterol absorbed at a higher rate 
than sitosterol. This difference in intestinal absorption may be due to a variation in the side chain, 
where the phytosterol uptake decreases with an increasing number of carbon atoms at C24 of the 
sterol chain (41). A small percentage of plant sterols is absorbed and packaged with chylomicrons 
for transport to the systemic circulation. From the liver, plant sterols are rapidly re-excreted into 
bile, and only small amounts are transported to other peripheral tissues by VLDL and LDL. Non-
absorbed plant sterols are metabolized by intestinal microflora in the same way as cholesterol, 
where metabolites corresponding to coprostanone and coprostanol are formed in the intestine 
(44). 
Phytosterol elimination takes place via the biliary route and appears to be more rapid than that of 
cholesterol (45). Accordingly, due to poor absorption in the intestine and faster excretion via bile, 
the pool of endogenous phytosterols is small compared with cholesterol.  
                 
3.3.2  Oxidized plant sterols and their cytotoxic effect 
Based on a limited number of studies on phytosterol oxidation processes, it has been concluded 
that the main oxidation route is generally the same as for cholesterol, resulting in the so-called 
oxyphytosterols or phytosterol oxidized products (POPs). Similarly, the analysis of 
oxyphytosterols follows the same procedures as in the case of COPs. Sitosterol oxidizes to  
7α- and 7β-hydroperoxysitosterol, which is reduced to 7α-hydroxysitosterol and  
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7β- hydroxysitosterol; and dehydration of hydroperoxysitosterol leads to the formation of  
7-ketositosterol.  Epoxidation of the double bond between C5 and C6 atoms of sitosterol results 
in 5α,6α- and 5β,6β-epoxysitosterol, which could be converted to sitostantriol (Figure 8). 
Campesterol and other plant sterols are converted to the corresponding products (46, 47). 
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                                       Figure 8 The chemical structure of some oxyphytosterols           
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Despite its similarity in chemical structure to cholesterol, Boberg et al. found that there is no 
significant conversion of C14 sitosterol into C24-bile acids in humans (48). By contrast, female 
Wistar rats can convert sitosterol into highly polar trihydroxylated C21-bile acids (49). 
In theory, the presence of an ethyl or methyl group at C24 should prevent or at least reduce side-
chain shortening after β-oxidation and thus inhibit conversion of plant sterol into bile acids by the 
same mechanism as that utilized for conversion of cholesterol into C24-bile acids. Furthermore, 
sitosterol is a poor substrate for 7α-hydroxylation, the initial and rate-limiting reaction in bile 
acid biosynthesis from cholesterol.  Plat et al. (9) have pointed out the presence of oxysterols in 
serum from sitosterolemic patients and in two lipid emulsions, but it is still unknown whether 
these compounds affect health, as has been suggested for oxycholesterols. Whereas a study 
mentioned that α-and β-epoxides of sitosterol were observed in the plasma of a patient with 
Waldenström’s macroglobulinaemia (50), the oxidized derivatives of phytosterols were also 
identified in plasma samples from thirteen healthy human volunteers (51). Grandgirard et al. (52) 
have shown in experimental animals that two of the main classes of oxyphytosterols (7-keto and 
epoxides) were absorbed at low rates, 4.7% of the given dose for epoxy derivatives and 1.5% for 
7-keto compounds. He also found that campesterol oxides are absorbed better than sitosterol 
oxides, confirming that the length of the side chain is important for movement through the 
intestinal barrier. More recently, when hamsters were fed 100 µg/g oxyphytosterols in their diet, 
no POPs were recovered from plasma or tissues; however, significant amounts of various POPs 
were found after the feeding level was increased above 500 µg/g, thus indicating that the 
incorporation process is dose-dependent (53). 
The cytotoxicity of oxyphytosterols has been studied in a culture-derived macrophage cell line, 
where the results showed that the oxides of sitosterol and campesterol have similar patterns of 
toxicity compared with oxycholesterols (54, 55). Adcox et al. (54) demonstrated that a mixture of 
sitosterol/campesterol oxides produces cell damage (which was monitored by lactate 
dehydrogenase leakage, cell viability and mitochondrial dehydrogenase activity) and that it may 
be due to hydroxy compounds identified in the mixtures of oxidized sterols. The damage caused 
by cholesterol oxides was greater than that caused by phytosterol oxides. In another study, 
Maguire et al. (55) demonstrated that sitosterol oxides exhibit patterns of toxicity similar to those 
of oxycholesterols on human monocytic U937 cells, which are a human cell line used as an in 
vitro model for monocyte/macrophage differentiation. 
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3.4  Sitosterolemia 
3.4.1  Definition 
Sitosterolemia, also known as phytosterolemia, is a rare autosomal recessively inherited sterol 
storage disorder. It was first recorded in 1974 (56) with a description of two 
normocholesterolemic siblings with large xanthomas and elevated plasma levels of the major 
plant sterols (27.1 and 17.7 mg/dl; where the normal range is < 1 mg/dl). This disease is 
characterized by the presence of tendon and tuberous xanthomas and by a strong predisposition to 
premature coronary artery disease, but with normal to moderately elevated plasma cholesterol 
levels (6, 57). Clinically it differs from familial hypercholesterolemia by its pattern of inheritance 
and by the diagnostic hallmark of elevated plasma phytosterol levels. Hemolysis, arthralgias and 
arthritis are also frequently associated with this disorder (6). 
Studies have demonstrated that the absorption of plant sterols in sitosterolemic patients is higher 
than in healthy subjects (58). The plant sterol concentrations in plasma from sitosterolemic 
patients vary between 16-27 % of total sterol content (58, 59 and60). Studies have also shown a 
significantly reduced rate of biliary phytosterol excretion (59). A lack of 7α-hydroxylation (6, 48) 
results in markedly expanded plant sterol pools.  
Biochemically, it was found that, the rate-limiting enzyme 7α-hydroxylase (which converts 
cholesterol into bile acids) is also reduced, due to competitive inhibition of this enzyme by 
sitosterol (61). Recently, it has been shown that the genetic defect in patients with sitosterolemia 
is due to mutations in either one of the two ATP-binding cassette (ABC) half-transporters, 
ABCG5 or ABCG8 (10). These two genes are expressed almost exclusively in the intestine and 
liver and are co-regulated by the nuclear hormone receptor, liver X receptor (LXR) (62).     
 
3.4.2  Genetic mutations in sitosterolemia 
No obvious differences in disease manifestation are apparent between patients with mutations in 
ABCG5 or in ABCG8. Interestingly, most Caucasian patients have mutations in ABCG8 whereas 
all Japanese individuals with sitosterolemia identified have mutations on ABCG5 (18, 63). Berge 
et al. (10) concluded that ABCG5 and ABCG8 normally cooperate to limit intestinal absorption 
and promote biliary excretion of sterols, and the mutated forms of these transporters predispose to 
sterol accumulation and atherosclerosis. Immediately following Berge’s report, Patel’s group 
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found that ABCG5 was mutated in nine unrelated sitosterolemic patients and also described 
mutations in ABCG8 in other patients (64). The identification of these genes should lead to a 
better understanding of the molecular mechanism(s) governing the highly selective absorption 
and retention of cholesterol by the body.  
 
3.4.3  Sitosterolemia and atherosclerosis   
The youngest sitosterolemic patient reported to have died due to CHD was a five-year-old girl 
with severe atheromatous narrowing of both coronary ostia (65). The association of high plant 
sterols levels in sitosterolemic subjects and atherosclerosis is documented in the work of Salen et 
al. (66). These authors confirmed the correlation between the plant sterols and atherosclerosis in 
an 18-year-old male with sitosterolemia who died suddenly of an acute myocardial infarction. 
Their findings indicate that atherosclerosis occurs prematurely in sitosterolemia and probably 
results from accelerated plasma sterol levels. Moreover, postmortem examination of the coronary 
and aortic vessels and myocardium revealed extensive atherosclerosis and microscopic infarction. 
Additionally, Hidaka (67) showed clinical signs of atherosclerosis obliterans, i.e., arterial bruit in 
femoral arteries and decreased ankle blood pressure, in two cases of four sitosterolemic patients. 
A case report refers to a 19-year-old man who presented with acute myocardial infarction with 
obstruction of one coronary artery. He proved to have sitosterolemia, which had resulted in 
juvenile coronary atherosclerotic lesions (68). A study by Sudhop et al. (69) raised questions 
regarding the role of plant sterols as a CHD risk factor as presumed by Glueck et al. in 
nonsterolemic subjects (70). It is not clear whether plant sterols are a risk factor in patients 
without sitosterolemia. 
 
3.4.4  Laboratory investigations 
Sitosterolemia must be considered in all patients with xanthomatosis and hypercholesterolemia, 
especially if there is a family history of premature cardiovascular disease. The diagnosis of 
sitosterolemia is established by demonstrating increased amounts of plant sterols and 5α-stanols 
in plasma and tissues. The usual enzymatic method does not distinguish sitosterol and other plant 
sterols from cholesterol. Therefore, gas-liquid chromatography needs to be used in addition to gas 
chromatography/mass spectroscopy or high-pressure liquid chromatography. 
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3.4.5  Treatment of sitosterolemia 
Dietary control is the first attempt in the treatment of sitosterolemia, with a diet containing a 
minimal amount of plant sterols recommended. When dietary treatment alone is insufficient, the 
following kinds of drugs may be considered: 
1 Bile acids binding resins (such as cholestyramine and colestipol) 
2 Cholesterol absorption inhibitor (ezetimibe)  
 
3.4.5.1  Bile acids binding resins 
Bile acids binding resins, also known as bile acid sequestrants, are a special class of cholesterol-
lowering agents. Resins exert their effect in the intestine, where they bind bile acids, preventing 
their reabsorption into the circulation and facilitating their subsequent loss in the feces. This 
interruption in the enterohepatic circulation of bile acids enhances the conversion of cholesterol 
to bile acids in the liver and results in a reduction of plasma cholesterol levels. This mechanism 
was also found to be effective in the treatment of sitosterolemia and reduction of plasma plant 
sterol concentrations (71,59), where the percent reduction in plasma sterol concentrations 
obtained with these drugs is greater than in similarly treated hypercholesterolemic subjects (72). 
Clinical improvement including disappearance of xanthomas, elimination of aortic murmur and 
decreased frequency of angina pectoris have been noted in several patients treated with 
cholestyramine (71). Bhattacharya et al. (73) showed that cholestyramine treatment of 
sitosterolemic patients (up to 12 g per day) reduces circulating levels of cholesterol, plant sterols 
and their 5α-analogues by about 50%. Lütjohann et al. (74) reported that the interruption of 
treatment with cholestyramine for six weeks resulted in an increase of circulating cholesterol by 
85%, campesterol by 57% and sitosterol by 40% compared to treatment with resins. 
 
3.4.5.2  Ezetimibe 
Ezetimibe, the first member of a new class of lipid-lowering drugs known as cholesterol 
absorption inhibitors, has been found to be useful in the treatment of primary 
hypercholesterolemia, due to its reducing effect on LDL-C, total cholesterol and apo B. It can 
also be used in combination therapy with statins for the treatment of familial 
hypercholesterolemia. The drug is absorbed into the intestinal epithelial cells and remains 
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associated with the apical cell membrane, where it is believed to interfere with the putative sterol 
transport system. This would prevent both free cholesterol and phytosterols from being 
transported into the cell from the intestinal lumen. 
Ezetimibe is rapidly absorbed; its time of maximum concentration is about one hour (75). Once 
absorbed, ezetimibe undergoes phase II metabolism in the intestine and liver to form an active 
glucuronide metabolite (76).  Both ezetimibe and its active metabolite are highly bound to plasma 
proteins, and the extensive enterohepatic circulation allows for recycling of the drug and prolongs 
the effective half-life (22 hr) (77). Ezetimibe impairs the intestinal absorption of dietary 
cholesterol as well as biliary cholesterol. 
The precise mechanism involved in the action of this drug remains unclear; however, several 
studies and experiments have attempted to identify a particular target or mechanism by which 
ezetimibe exerts its sterol-lowering effect. The activity of ACAT is not inhibited by ezetimibe 
(78), and other studies indicate that SR-BI is not the site of ezetimibe action (79). Ezetimibe also 
has no effect on ABCG5, ABCG8 and various intestinal adenosine triphosphate (ATP) binding 
cassette (ABC) transporters (10). More recently, Altmann and Davis (16, 43) found that the 
profile of cholesterol absorption in NPC1L1 null mice closely resembles the profile for an 
ezetimibe-treated animal, suggesting that ezetimibe acts through the pathway that contains 
NPC1L1 protein. Sudhop et al. (11) have shown that treatment with ezetimibe for two weeks 
reduces cholesterol absorption by 54% compared with the placebo group, with the concentrations 
of both LDL and total cholesterol being reduced by 20.4% and 15%, respectively.  However, 
campesterol and sitosterol concentrations were also reduced by 48% and 41%, respectively. The 
effect of ezetimibe on the plant sterols in plasma was studied by Salen et al. in patients with 
sitosterolemia (12). This work has clearly indicated that a dose of 10 mg ezetimibe per day for 
eight weeks leads to a reduction in sitosterol concentration of 21%, compared with a 
nonsignificant rise of 4% in the group receiving a placebo. Campesterol concentration was also 
significantly decreased 24% by ezetimibe treatment, whereas with administration of a placebo it 
slightly increased 3% . It is interesting to note the reduction in xanthomas in the ezetimibe-treated 
group relative to the placebo group after eight weeks of treatment (12). Whether this decrease in 
xanthomas indicates that other complications including atherosclerosis and hemolysis may be 
reduced with ezetimibe remains to be elucidated. 
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4   Intravenous lipid emulsion as parenteral nutrition 
The essential components of parenteral nutrition are fluids, carbohydrates, electrolytes, proteins, 
lipids, vitamins and minerals. Intravenous lipid emulsions are a major source of energy; they 
provide the required essential fatty acids and help to improve nitrogen balance. There are two 
types of lipid emulsions currently used in parenteral nutrition: 1) lipid emulsions prepared from 
soybean oil, which are composed of long-chain triacylglycerols and 2) lipid emulsions composed 
of half medium-chain triacylglycerols and half long triacylglycerols from soybean oil; both of 
these components may contain phytosterols. The cholesterol and phytosterol content of some 
lipid emulsions has been determined by gas chromatography-mass spectroscopy, and the results 
are shown in Table 1 (80). 
 
 Table 1  Concentrations (mg/dl) of plant sterols in samples of four commercially available lipid      
 emulsions (80). 
   
 
Lipid emulsion 
 
Ivelip 20%  
  
Lipofundin 20% 
                    
                               
 
Lipofundin 20%٭ 
     
 
  
Intralipid 20% 
Cholesterol      27.0          0.0         75.3        44.8 
Campesterol      22.8        31.2         20.8          8.4 
Stigmasterol      14.8        27.2         11.5          7.4 
Sitosterol      42.2        77.0         45.1        26.9 
Sitostanol        1.7          0.0           0.0          1.7 
Total sterols    108.5      135.4       152.7        89.2 
٭ MCT/LCT   medium chain  triglycerols / long chain triglycerols.       
                   
A new intravenous lipid emulsion consisting of a mixture of soybean and olive oils has been 
studied to assess its safety and efficacy for children (81). The use of lipid emulsions has been 
associated with certain complications in neonates, including hyperlipidemia, hyperbilirubinemia 
and changes in pulmonary function when the rate of administration is too high (82). Cholestasis 
is the most serious metabolic complication seen with long-term parenteral nutrition in neonates 
(83) and may result in biliary cirrhosis or end-stage liver disease. Parenteral nutrition-associated 
cholestasis is particularly common in small premature infants due to reduced bile acid synthesis 
rates and pool sizes and an immature bile secretory system. One important factor affecting the 
incidence of parenteral nutrition-associated cholestasis is the duration of intravenous feeding 
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(84). The observation that children who were receiving parenteral lipid emulsion and showed 
high plasma phytosterol concentration developed cholestasis led to the hypothesis that 
accumulation of these plant sterols contributes to cholestasis (84). It was hypothesized that the 
liver has a limited capacity for handling plant sterols. Under normal circumstances this limited 
capacity is not important, since plant sterols are poorly absorbed from the diet. In patients 
receiving parenteral nutrition, however, the plant sterols given intravenously must be metabolized 
or excreted. Conversion of the plant sterols to bile acids is inefficient, and they may inhibit the 
conversion of cholesterol to bile acids (85, 86). Plant sterols secreted into bile are likely to be less 
soluble than cholesterol and may precipitate if bile salt concentrations are reduced. Children 
requiring parenteral nutrition often have a reduced bile salt pool in their enterohepatic circulation; 
if precipitation of sterols occurs, it contributes to biliary sludge. 
It has been proposed that sterol accumulation in the liver and/or precipitation in bile play a 
significant role in the pathogenesis of parenteral nutrition-associated liver disease (80, 84). 
Clayton et al. (84) studied 29 children aged two months to nine years who were receiving 
parenteral nutrition and 29 matched controls with ages ranging from three months to fourteen 
years. The study showed that five children with severe parenteral nutrition-associated liver 
disease had plasma concentrations of phytosterols and sitostanol that were as high as those seen 
in patients with sitosterolemia (see Table 2). A reduction in lipid emulsion intake was associated 
with a decrease in plasma phytosterol concentration and an improvement in liver function and 
platelet counts. 
 
  Table 2  Sterol and stanol concentrations in patients receiving parenteral nutrition and in control        
   subjects (82). 
    
                                            Concentration in plasma ( mg/dl )       
                                  Control                                 Patients receiving total PN 
 
   Analyte            Normal liver function        Mild liver dysfunction      Severe liver dysfunction 
 
   Campesterol 
         
          1.0 ± 0.2 
        
                2.3 ± 0.5    
                  
                   10.6 ± 1.1 
   Stigmasterol                 0                 1.1 ± 0.3                      6.5 ± 1.2 
   Sitosterol           0.6 ± 0.1                 6.3 ± 1.7                    39.3 ± 3.8 
   Sitostanol                 0                 0.6 ± 0.2                      3.7 ± 0.8 
   Cholesterol       176.1 ± 17.7             182.8 ± 14.7                  185.8 ± 13.9 
   Cholestanol         0.03 ± 0.01                 0.2 ± 0.1                      0.8 ± 0.5 
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Plat et al. (9) showed the presence of oxyphytosterols in two frequently used soybeans oil-based 
lipid emulsions in total parenteral nutrition protocols, where emulsion A contained lower levels of 
plant sterols and more cholesterol than emulsion B (Table 3). Oxidized plant sterol concentrations 
were somewhat higher in emulsion B. The ratios of oxidized sitosterol to sitosterol, however, 
were comparable: 0.038 in emulsion A and 0.041 in emulsion B. This suggests that the higher 
oxyphytosterol concentrations in emulsion B were simply due to higher plant sterol 
concentrations. 
 
                Table 3  Plant sterol and oxidized sitosterol concentrations in lipid emulsions (9). 
                 
 Emulsion A    Emulsion 
B 
Cholesterol (mg/dl)       29.8        17.8 
Plant sterols (mg/dl)a       11.3        27.7 
Sitosterol (mg/dl)         8.6        20.1 
Campesterol (mg/dl)         2.7          7.6 
7-ketositosterol (µg/ml)         0.70          1.26 
7β-hydroxysitosterol (µg/ml)         0.65          0.37 
5α,6α-Epoxysitosterol (µg/ml)         2.73          9.24 
3β,5α,6β-tri-hydroxysitosterol (µg/ml)         0.16          0.49 
7α-hydroxycholesterol (ng/ml)       19.50          9.70 
                a  Plant sterols are calculated as the sum of sitosterol and campesterol 
 
 
Because these emulsions are currently used in neonatal parenteral nutrition, their direct venous 
introduction might be potentially dangerous because of the possible atherogenic role of 
cholesterol and plant sterol oxidation products. 
 
 
 
 
 
 
 
 
 
Methods  
 
  
5   Methods 
A - First study 
5.1  Chemicals 
1. Solvents: 
Cyclohexane, dichloromethane, phosphoric acid, ethanol, toluene, propanol and hexane    
were purchased from Merck-Darmstadt (Germany). All were of analytical grade. 
2. Potassium hydroxide and sodium chloride (analytical grade) were obtained from Merck-
Darmstadt (Germany). 
3. Silylation reagent: dry pyridine, hexamethyldisilazane, trimethylchlorosilane (TMS) 3:2:1 
(v/v/v). 
4. Oxycholesterols: 
Cholesterol, 7β-hydroxycholesterol and 7-ketocholesterol were from Sigma-Aldrich 
(Germany), while 7α-hydroxycholesterol was from Steroloids (USA). 
3β, 5α, 6β-cholestantriol and epoxycholesterol were synthesized in the lab of clinical 
pharmacology department in Bonn university  (87). 
5. All deuterated oxycholesterol compounds (26,26,26,27,27,27-d6-cholesterol, 26,26,26,27, 
27,27-d6-7α-hydroxycholesterol, 26,26,26,27,27,27-d6-7β-hydroxycholesterol, 26,26,26, 
27,27,27-d6-3β,5α,6β-cholestantriol, 26,26,26,27,27,27-d6-7-ketocholesterol, 26,26,26,27, 
27,27-d6-5α,6α-epoxycholesterol and 26,26,26,27,27,27-d6-5β,6β-epoxy-cholesterol) 
      as internal standards (ISTD) were prepared according to Plat et al. (9). 
6. Oxyphytosterols: 
      Sitosterol  was  from  Sigma-Aldrich (Germany)  and deuterated sitosterol  (2,2,4,4,6-d5-  
      sitosterol/campesterol) was from Sugaris GmbH (Germany).         
      All other deuterated oxyphytosterol compounds (2,2,4,4,6-d5-7α-hydroxysitosterol/   
      campesterol, 2,2,4,4,6-d5-7β-hydroxysitosterol/campesterol, 2,2,4,4,6-d5-3β,5α,6β– 
sitostantriol/campestantriol, 2,2,4,4,6-d5-7-ketositosterol/campesterol, 2,2,4,4,6-d5-5α, 
6α-epoxysitosterol/campesterol and 2,2,4,4,6-d5-5β,6β-epoxysitosterol/campesterol) as 
      internal standards (ISTD) and non-deuterated oxyphytosterols were prepared according to 
Plat et al. (9).  
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5.2  Sample collection 
Before and after eight weeks of treatment with ezetimibe (10 mg/day), blood samples were taken 
from 13 sitosterolemic patients, ranging in age from 12 to 57 years ( their weight ranged between 
39 and 98 kg).  Four of the patients were being treated with statins (two of them with simvastatin 
40 and 20 mg once a day and the other two were with atrovastatin in a dose of 20 mg daily in a 
tablet form)  and three patients were taking bile acid binding resins (one of them was with 
cholestyramine powder in a dose of 8 gm daily and the other two patients were with cholestipol 
tablets in a dose of 16 gm daily) , whereas the other six patients were not being treated with 
drugs.  
Soybean oil-lipid emulsion (lipofundinR 10% and lipovenöseR) used in total parenteral nutrition 
protocols was analyzed for oxyphytosterols and oxycholesterols by the same procedures as 
described for serum samples. 
The following measurements of oxysterols were carried out: 
1 Oxyphytosterols and oxycholesterols in the serum from patients with sitosterolemia as 
compared with serum samples from normolipemic controls 
2 The effect of ezetimibe on oxyphytosterol and oxycholesterol concentrations in the three 
different groups of patients (those being treated with statins, with bile acid binding resins and 
without drugs) 
3 Oxyphytosterols and oxycholesterols in two samples of commercially available lipid 
emulsions used as intravenous nutrition 
4 Oxyphytosterols and oxycholesterols in serum from nine patients receiving intravenous lipid 
emulsions. 
5.3  GC-MS analysis 
5.3.1  Sample preparation  
5.3.1.1  Alkaline hydrolysis and extraction 
The serum samples from patients were kept at -80 °C with 10 µl BHT (25 mg/ml in methanol). 
By modifying the method used by Dzeletovic et al. (88), one ml of serum was taken in a 50 ml 
test tube and 100 µl of internal standard (ISTD) were added to the serum sample. Before 
saponification and extraction, the serum sample was extensively saturated with argon to minimize 
autoxidation. Saponification was carried out by adding 10 ml of 0.35 M ethanolic KOH in a 
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closed tube under argon for 2 hours at room temperature. 130 µl of phosphoric acid (50% , v/v in 
H2O) was added after saponification to neutralize the solution, followed by addition of 6 ml NaCl 
solution in H2O (9 mg/ml). The unsaponifiable part was extracted by liquid-liquid partitioning 
into dichloromethane (20 ml). The lower layer was transferred into a conical flask and dried by 
evaporation under vacuum. The residue was dissolved in 2 ml ethanol and again evaporated 
under vacuum to remove all traces of water. The residue was dissolved in 1 ml toluene. 
5.3.1.2  Solid-phase extraction 
Silica cartridges (Bond Elut, bonded phase SI, 100 mg, 1 ml; Varian, Harbor City, CA 90710, 
USA) were eluted with 2 ml hexane before the toluene fraction was loaded. Neutral sterols 
including cholesterol, sitosterol and campesterol were eluted from the column with 10 ml 0.25% 
isopropanol in cyclohexane (v/v), whereas the absorbed oxysterols were eluted with 8 ml of 30% 
isopropanol in cyclohexane (v/v). 
The oxysterols fraction was dried under vacuum. Finally, the oxidized sterols were dissolved in 
500 µl cyclohexane and transferred to an injection vial, dried with nitrogen and silylated by 
addition of 100 µl of TMS. Then the vial was heated for 1 hr at 90 °C , after which the sample 
was diluted with 200 µl cyclohexane for GC-MS measurement. 
To minimize the autoxidation of both cholesterol and plant sterols, the samples were  kept at  
-80 ºC with BHT (which acts as an antioxidant). In addition, all the processing was done under 
cold conditions. Samples were saturated with argon, thus creating an inert atmosphere. Isotope-
labelled sterols were added to trace the loss of oxysterols during sample processing (88, 89). 
5.3.2  Chromatographic conditions 
Oxyphytosterols and oxycholesterols were analyzed by GC-MS as TMS derivatives, where 2 µl 
of the TMS derivatives in cyclohexane were injected via an AS2000 autosampler (Thermoquest 
CE Instruments, Egelsbach, Germany) on a Trace GC2000 (Thermoquest CE Instruments) gas 
chromatograph equipped with a DB-XLB column (30 m x 0.25 mm internal diameter, 0.25 µm 
film thickness) coupled to a trace MS (Thermoquest CE Instruments). The analysis was carried 
out in single ion monitoring (SIM) mode, making m/z the primary resolving parameter other than 
only retention time. The injector temperature was set at 280 °C. Helium was used as carrier gas 
(constant flow 1 ml/min). The oven temperature gradient was programmed for 150 s at 150 °C, 
then increased by 10 °C/min toward 290 °C, and then increased by 7 °C/min toward 320 °C and 
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kept there for 20 minutes. Thus, one analytical run lasted approximately 42 minutes. The ions and 
retention times of all individual compounds are given in Table 4. In addition to plant sterols and 
oxyphytosterols, also retention times and m/z  values of cholesterol oxidation products (and also 
of 26,26,26,27,27,27-d6-cholesterol oxidation products) are shown, which illustrates that 
interference of oxycholesterols and oxyphytosterols in GC-MS identification is not a problem. 
 
 
Table 4  Retention times and m/z values of oxycholesterols and oxyphytosterols. 
 
                      
                            D0 
                        
                      D5/6 
Compound TMS    Retention Time m/z  Retention Time  m/z 
Cholesterol           18.24 458         18.15 464 
7α-hydroxycholesterol           17.39 456         17.17 462 
7β-hydroxycholesterol           18.64 456         18.57 462 
3β,5α,6β-cholestantriol           20.22 456         20.14 462 
5α,6α-epoxycholesterol           19.95 384         19.75 390 
5β,6β-epoxycholesterol           19.54 384         19.38 390 
7-Ketocholesterol           21.50 472         21.41 478 
Sitosterol           19.98 486         19.88 492 
7α-hydroxysitosterol           18.87 484         18.87 488 
7β-hydroxysitosterol           20.27 484         20.24 488 
3β,5α,6β-sitostantriol           22.15 484         21.93 488 
5α,6α-epoxysitosterol           21.62 412         21.54 416 
5β,6β-epoxysitosterol           21.33 412         21.27 416 
7-ketositosterol           23.48 500         23.41 504 
Campesterol           19.13 472         19.05 478 
7α-hydroxycampesterol           18.11 470         18.10 474 
7β-hydroxycampesterol           19.51 470         19.49 474 
3β,5α,6β-campestantriol           21.24 470         21.09 474 
5α,6α-epoxycampesterol           20.73 398         20.68 402 
 5β,6β-epoxycampesterol           20.45  398         20.42 402 
7-ketocampesterol           22.45 486         22.39 490 
 
5.3.3  Derivatization 
Oxyphytosterols and oxycholesterols were analyzed as TMS derivatives by silylating them using 
dry pyridine, hexamethyldisilazane, trimethylchlorosilane (TMS) 3:2:1 (v/v/v). by silylation, 
active hydrogen is replaced by an alkylsilyl group.                                                                                                   
100 µl of TMS were added to the sample in GC vials and heated at 90° C for one hour. Compared 
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with their parent compounds, silyl derivatives are more volatile, less polar and more thermally 
stable. As a result, GC separation is improved and detection is enhanced. The silylation is usually 
conducted in pyridine medium, which must be anhydrous─since water competes with TMS, 
moisture in tubes and reagents could lead to incomplete silylation. 
5.3.4   Selected ion monitoring 
The unlabelled and labelled oxidized sterol derivatives were analyzed by SIM mode using 
specific masses counting. Characteristic ions for oxycholesterols and oxyphytosterols were 
monitored (see Table 4). 
5.3.5  Calibration  
Calibration curves for all individual compounds were calculated after preparing a standard 
mixture of all compounds by dissolving crystals of synthesized standards in cyclohexane (except 
trihydroxy-sterols, which were dissolved in dichloromethane) to a final concentration of 
1 mg/10 ml.  100 µl of deuterated solutions of both oxycholesterols and oxyphytosterols were 
added to the vials labelled as follows: 0, 10, 20, 50, 80 and 100. Non-deuterated solutions were 
added in volumes of 0, 10, 20, 50, 80 and 100 µl. The vials were evaporated by nitrogen, then 
silylated with 100 µl TMS and heated at 90 ˚C for one hour and diluted with 100 µl cyclohexane 
for GC-MS measurement. 
5.3.6  Quantification 
Quantification of oxyphytosterols and oxycholesterols was based on the ratio between the 
calculated peak area from selected ions of corresponding different oxidized sterols and their 
corresponding labelled internal standards. The concentration of different oxidized sterols was 
then calculated using the linear regression of the calibration curve. 
 
5.3.7  Method validation 
5.3.7.1  Specificity 
Cholesterol, sitosterol, campesterol, oxycholesterols and oxyphytosterols were identified on the 
basis of retention time, the appearance of labelled analogous and the specific m/z of both labelled 
and unlabelled compounds. 
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5.3.7.2  Linearity 
The correlation coefficient, y-intercept and slope of the regression line of 7α- hydroxycholesterol 
as example for linearity are shown in Figure 10. In order to show the deviations from linearity, 
the response factor (mi) was calculated using the following formula: 
                                              
                                                            mi = (y-b)/x 
Where; 
b: Y-intercept of calibration curve 
y: ratio between nondeuterated and deuterated compound 
x: amount of the compound  
  
Table 5  Determination of linear range of 7α- hydroxycholesterol. 
 
  Amount (µg) 
        (x) 
      D6 
 
      D0     D0/D6 
     ( y) 
Regression line Response factor 
       (mi) 
         0    63456857     166623     0.002626          0 
      0.2088    70723207     21006062     0.297018    1.330067 
      0.4176    70277274     42409735     0.603463    1.398858 
      1.044    41245720     60495716     1.466715    1.386413 
      1.6704    41384223     94571463     2.285206    1.356505 
     2.088    50000713     142855832     2.857076 
 
m=1.3716 
b= 0.0133 
r2= 0.9998 
 
   1.359088 
 
In addition to the correlation coefficient and y-intercept, 10% more or less than the response 
factor of the regression line (m) was used as a range to accept and evaluate the linearity data, 
which was in the range of 1.37±0.14 (1.23-1.51) (Figure 10).  
For 7α- hydroxycholesterol, all response factors (m) were in the range between 1.23 and 1.51; 
therefore the linear range of the regression line was between 0.2088 and 2.088 µg (Figure 9). 
A linear relationship was observed over the range shown in Table 6 for all oxycholesterols and 
oxyphytosterols except for 7-ketositosterol and 7-ketocampesterol, which were calculated by 
using a polynomic curve. 
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       * Response factor 
                 
                 Figure 9  Calibration curve and linear range of 7α- hydroxycholesterol 
           
             Table 6  Linear range for quantification of oxycholesterols and oxyphytosterols.  
 
        Oxysterols     Linear range (µg)      
  7α-hydroxycholesterol         0.208-2.08 
  7β-hydroxycholesterol         0.112-1.12 
  7-ketocholesterol         0.329-3.29 
  3β,5α,6β-cholestantriol         0.140-1.40 
  7α-hydroxysitosterol         0.039-0.392 
  7β-hydroxysitosterol         0.067-0.674 
  3β,5α,6β-sitostantriol         0.098-0.981 
  7α-hydroxycampesterol         0.020-0.206 
  7β-hydroxycampesterol         0.046-0.463 
  3β,5α,6β-
campestantriol 
        0.062-0.629 
0
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5.3.7.3  Analytical recovery 
Tables 7a, b and c show the results of several experiments which were performed to determine 
the percentage recovery of oxycholesterols and oxyphytosterols from spiked serum samples (88, 
90). 
Serum samples were analyzed before and after addition of 10, 20 and 100 µl of standard mixtures 
of oxycholesterols and oxyphytosterols. Tables 7a, 7b and 7c show that when the amount of 
standard mixture of oxysterols added to the serum decreases, the percentage recovery decreases. 
As in case of 10 µl, the percentage recovery was between 55% and 76%, whereas in case of  
100 µl, the percentage recovery was between 82% and 123%. 
 
 
Table 7a  Recovery of oxycholesterols and oxyphytosterols from spiked serum (10 µl). 
 
               Oxysterols Unspiked samples 
       (µg/ml) a 
Spiked samples  
         (µg/ml) b 
Amount (µg) 
added in 10 µl  
Recovery
   ( % )       
7α-hydroxycholesterol    0.12 ± 0.0009   0.23 ± 0.010           0.21      55 
7β-hydroxycholesterol    0.06 ± 0.002   0.13 ± 0.001          0.11      62 
3β,5α,6β-cholestantriol    0.06 ± 0.002   0.14 ± 0.003          0.14      60 
7-ketocholesterol    0.13 ± 0.009   0.36 ± 0.070          0.33      69 
7α-hydroxysitosterol    0.001 ± 0.0007   0.03 ± 0.001          0.04      69 
7β-hydroxysitosterol     0.007 ± 0.0015   0.05 ± 0.003          0.07      66 
3β,5α,6β-sitostantriol    0.005 ± 0.0016   0.06 ± 0.003          0.10      61 
7-ketositosterol    0.012 ± 0.002   0.01 ± 0.002          0.04      60 
7α-hydroxycampesterol    0.001 ± 0.0001   0.02 ± 0.001          0.21      76 
7β-hydroxycampesterol    0.002 ± 0.0001   0.04 ± 0.003          0.05      70 
3β,5α,6β-campestantriol    0.001 ± 0.0001   0.04 ± 0.002          0.07      63 
7-ketocampesterol    0.006 ± 0.001   0.03 ± 0.003          0.03      68 
a  amount in µg ; mean ± SD (n=3); Sample volume 1.0 ml 
b  amount in µg ; mean ± SD (n=6); Sample volume 1.0 ml 
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Table 7b  Recovery of oxycholesterols and oxyphytosterols from spiked serum (20 µl). 
 
            Oxysterols Unspiked samples 
       (µg/ml) a 
Spiked samples  
         (µg/ml) b 
 Amount (µg) 
added in 20 µl  
Recovery 
   ( % )       
7α-hydroxycholesterol    0.12 ± 0.0009   0.42 ± 0.010         0.42      71 
7β-hydroxycholesterol    0.06 ± 0.002   0.26 ± 0.006         0.22      86 
 3β,5α,6β-cholestantriol    0.06 ± 0.002   0.25 ± 0.023         0.28      70 
7-ketocholesterol    0.13 ± 0.009   0.60 ± 0.028         0.66      71 
7α-hydroxysitosterol    0.001 ± 0.0007   0.06 ± 0.005         0.08      76 
7β-hydroxysitosterol     0.007 ± 0.0015   0.11 ± 0.001         0.13      76 
3β,5α,6β-sitostantriol    0.005 ± 0.0016   0.15 ± 0.005         0.20      74 
7-ketositosterol    0.012 ± 0.002   0.09 ± 0.007         0.09      82 
7α-hydroxycampesterol    0.001 ± 0.0001   0.03 ± 0.001         0.04      81 
7β-hydroxycampesterol    0.002 ± 0.0001   0.08 ± 0.005         0.09      78 
3β,5α,6β-campestantriol    0.001 ± 0.0001   0.96 ± 0.003         0.13      76 
7-ketocampesterol    0.006 ± 0.001   0.06 ± 0.005         0.06      92 
a  amount in µg ; mean ± SD (n=3); Sample volume 1.0 ml 
b  amount in µg ; mean ± SD (n=3); Sample volume 1.0 ml 
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Table 7c  Recovery of  oxycholesterols and oxyphytosterols from spiked serum (100 µl).    
 
             Oxysterols Unspiked samples 
       (µg/ml) a 
Spiked samples  
         (µg/ml) b 
  Amount (µg) 
added in 100 µl  
Recovery 
   ( % )        
7α-hydroxycholesterol    0.12 ± 0.0009      2.20 ± 0.07          2.09      100 
7β-hydroxycholesterol    0.06 ± 0.002      1.10 ± 0.03          1.12       92 
3β,5α,6β-cholestantriol    0.06 ± 0.002      1.20 ± 0.02          1.40        82 
7-ketocholesterol    0.13 ± 0.009      3.19 ± 0.07          3.29        93 
7α-hydroxysitosterol    0.001 ± 0.0007      0.41 ± 0.004           0.39        92 
7β-hydroxysitosterol     0.007 ± 0.0015      0.75 ± 0.008          0.67      111 
3β,5α,6β-sitostantriol    0.005 ± 0.0016      1.01 ± 0.018          0.98      100 
7-ketositosterol    0.012 ± 0.002      0.55 ± 0.011          0.45      123 
7α-hydroxycampesterol    0.001 ± 0.0001      0.21 ± 0.006          0.02      103 
7β-hydroxycampesterol    0.002 ± 0.0001      0.46 ± 0.005          0.46      102 
3β,5α,6β-campestantriol    0.001 ± 0.0001      0.64 ± 0.012          0.63        99 
7-ketocampesterol    0.006 ± 0.001      0.38 ± 0.010          0.32      121 
a  amount in µg ; mean ± SD (n=3); Sample volume 1.0 ml 
b  amount in µg ; mean ± SD (n=3); Sample volume 1.0 ml 
 
 
5.3.7.4  Accuracy 
 
The accuracy of an analytical method describes the closeness of the mean test results obtained by 
the method to the true value (concentration) of the analyte. In this work accuracy was determined 
by replicate analysis of samples containing 3 different known amounts of the analyte using ten  
determinations per concentration. The mean values were  within 15% of the actual value. 
5.3.7.5  Precision 
The repeatability of the method was evaluated using six spiked serum samples, each of which 
was analyzed after the addition of 100 µl of oxysterols standard mixture following the procedure 
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of extraction, derivatization and GC-MS analysis. Table 8 shows the means, SD and variation 
coefficients of all compounds. 
 
 Table 8  Repeatability for the determination of oxysterols by GC-MS. 
 
Sample no.  1 2 3 4 5 6 Mean   SD CV 
                                                                    Oxysterols (µg/ml) 
7α-hydroxycholesterol 2.11 2.31 2.29 2.14 2.17 2.21 2.20 0.07 3.3 
7β-hydroxycholesterol 1.14 1.07 1.16 1.13 1.07 1.07 1.11 0.04 3.3 
3β,5α,6β-cholestantriol 1.21 1.25 1.18 1.19 1.21 1.19 1.21 0.02 1.8 
7-ketocholesterol 3.11 3.30 3.26 3.16 3.11 3.24 3.20 0.07 2.3 
7α-hydroxysitosterol 0.40 0.40 0.41 0.42 0.40 0.41 0.41 0.01 1.1 
7β-hydroxysitosterol 0.75 0.76 0.74 0.76 0.75 0.75 0.75 0.01 1.1 
3β,5α,6β-sitostantriol 1.00 0.98 1.00 1.00 1.03 1.03 1.01 0.02 1.9 
7-ketositosterol 0.54 0.53 0.55 0.56 0.55 0.56 0.55 0.01 2.2 
7α-hydroxycampesterol 0.22 0.21 0.20 0.22 0.21 0.22 0.21 0.01 3.2 
7β-hydroxycampesterol 0.47 0.46 0.46 0.47 0.46 0.47 0.46 0.01 1.2 
3β,5α,6β-campestantriol 0.63 0.63 0.65 0.65 0.64 0.65 0.64 0.01 2.0 
7-ketocampesterol 0.37 0.37 0.38 0.39 0.39 0.39 0.38 0.01 2.6 
 
 
5.3.7.6   Limit of detection and limit of quantification 
The detection limit of the assay was estimated by determining the signal-to-noise ratios of the 
peaks of the unlabelled compounds using the software (XcaliburTM Version 1,2. Finnigan Corp. 
1998-2000) supplied with the mass spectrometer controlling program. The detection limit can be 
defined as the smallest concentration of analyte that can be reliably detected by the instrumental 
method. This smallest concentration was estimated by using the following formula: 
 
                     Limit of detection = amount of analyte . 3/signal: ratio recorded (90). 
 
The limit of quantification is the smallest amount of analyte that can be quantified. It can be 
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calculated as 3 times the limit of detection: 
             Limit of quantification = 3 . limit of detection. 
Table 9 shows the detection limit and quantification limit of all oxysterols. 
 
            Table 9  Detection limit and quantification limit of oxysterols. 
 
         Oxysterols Detection limit  (ng/ml)  Quantification limit 
(ng/ml) 
7α-hydroxycholesterol             0.15                   0.44 
7β-hydroxycholesterol             0.13                   0.40 
3β,5α,6β-cholestantriol             0.89                   2.67 
7-ketocholesterol             0.98                   2.95 
7α-hydroxysitosterol             0.26                   0.77 
7β-hydroxysitosterol              0.45                   1.36 
3β,5α,6β-sitostantriol             0.81                   2.42 
7-ketositosterol             5.91                 17.72 
7α-hydroxycampesterol             0.15                   0.46 
7β-hydroxycampesterol             0.42                   1.25 
3β,5α,6β-campestantriol             0.59                   1.77 
7-ketocampesterol             2.22                   6.66 
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B - second study 
5.4  Chemicals 
1. Sodium hydroxide, ethanol, cyclopean, pyridine and silylation reagent (dry pyridine,          
    hexamethyldisilazane, trimethylchlorosilane (TMS) 3:2:1 (v/v/v)) were purchased from 
    Merck, Darmstadt. 
2. 5α-cholestane as internal standard was purchased from Serva Electrophoresis GmbH, 
     Heidelberg.  All the chemicals were of analytical grade. 
5.5  Sample collection 
The blood samples were collected from sitosterolemic patients and the serum was obtained by 
centrifugation. The serum samples were kept at -20 °C after addition of 10 µl butylated 
hydroxytoluene (BHT) (25 mg/ml in ethanol). 
The patients were between 9 and 72 years old (11 males and 20 females and their weight ranged 
between 37 to 103 Kg). Ten of these patients were being treated with bile acid binding resins 
(five patients were with cholestyramine powder in a dose ranged between 4 to 16 gm daily, where 
the other five patients were with cholestipol in a dose of 6 to 20 gm daily), seven with statins 
(two patients were with simvastatin 20 and 40 mg daily,  two patients were with cholestin tablets 
in a dose of 600 mg daily, where the other two patients were with atrovastatin 20 mg per day and 
the last patient was with fluvastatin 60 mg daily)  and four with a combined therapy of statins and 
resins (atrovastatin 10-40 mg plus cholestyramine in a dose of 4-16 gm). 
In order to see the effect of different drug treatment on the level of sterols, stanols and cholesterol 
precursors like lathosterol, ten patients who were receiving no drug treatment for sitosterolemia 
were also included.  
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5.6  GC analysis 
5.6.1  Sample preparation 
50 µl of 5α-cholestane (mg/ml) and 10 µl of epicoprostanol (100 µg/ml) were added to 100 µl of 
the serum sample as internal and external standards, respectively. Alkaline hydrolysis was 
performed at 68 °C for 1 hour by addition of 1 ml 1 M ethanolic sodium hydroxide. The solution 
cooled at room temperature and 500 µl of distilled water were added. The unsaponified lipid was 
extracted three times into 3 ml of cyclohexane. The combined organic phases were dried under 
nitrogen at 65 °C. 500 µl of the n-decane were added to the residue and transferred into micro-
vials for GC-analysis after derivatization process. 
5.6.2  Derivatization 
Sterols and stanols were analyzed as TMS derivatives by silylating the hydroxyl groups of these 
compounds using dry pyridine, hexamethyldisilazane, trimethylchlorosilane (TMS) 3:2:1 (v/v/v). 
by silylation, active hydrogen is replaced by an alkylsilyl group. 
 
5.6.3  Chromatographic conditions   
Sterols and stanols were analyzed by GC as TMS derivatives, where 2 µl of TMS derivatives 
were injected automatically via an HP 7683 injector at 280 °C. Hydrogen was used as carrier gas 
(constant flow 1.1 ml/min) with an inlet pressure of 9.97 psi. The oven temperature was kept at 
150 °C for 3 min. and raised at a rate of 30 °C/min to a final temperature of 290 °C, which was 
maintained for 22.33 min. The different compounds of sterols and stanols were separated on a 
dimethylsilicone capillary column (J and W, Folsom, USA) (30 m x 0.25 mm internal diameter, 
0.25 µm film thickness) in a Hewlett Packard (HP) GC 5890. 
The entire GC was controlled and the total chromatogram was integrated automatically by the 
computer software (Rev. A. 08.03 [847], Agilent Technologies 1990-2000). The exact retention 
times as gained from a serum standard chromatogram could be taken from a calibration table. 
The calibration table included information on the sterol retention times, internal standard 
qualification and amount. The information about the usual integration parameters was saved in an 
integration event table. After an automatic inspection of basic integration, the integration of each 
peak was inspected again.  If the peak was not integrated correctly, the integration was performed 
manually. The final integration results including the raw data and a chromatogram of the serum 
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sample were printed out and saved in a file. The raw data and the concentrations for the different 
sterols were converted from the HP data-file to an EXCEL spreadsheet. 
5.6.3 Method Validation 
The gas chromatographic method used in this study to measure the concentration of cholesterol 
and non-cholesterol sterols in plasma was developed and validated at the Department of Clinical 
Pharmacology, University of Bonn (VALGCSTER 1.1- Validation of analytical procedures: 
methodology validated by Dr. Dr. D. Lütjohann) using its associated SOP (Standard Operating  
Procedure Serum Sterols GC SOP-KP-3.5, dated 12.08.2002; Dr.Dr. D Lütjohann). 
 
5.6.5  Statistical analysis 
The one-way analysis of variance (ANOVA) test was used to see whether there is a significant 
change between the different groups when the samples distributed normally. When the samples 
were not in a normal distribution, non-parametric tests (such as the Kruskal-Wallis and Mann-
Whitney tests) were used. The Kruskal-Wallis test was used to determine whether there was a 
significant change between different drug treatments, whereas the Mann-Whitney test was used 
to find out between which two drug treatments this significant change exists. 
The Anderson-Darling test was used to determine whether the samples distributed normally or 
not, where P= 0.05 was used as a significant level. 
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6   Results 
A. Results of the first study  
6.1  Cholesterol oxidation products (COPs) 
6.1.1  COPs in lipid emulsions as parenteral nutrition 
The aim of this preliminary study was to assess the possible presence of cholesterol oxidation 
products (COPs) and plant sterol oxidation products (POPs) in two intravenous lipid emulsions 
with different fatty acid compositions (lipofundinR 10% and lipovenöseR). The emulsions were 
analyzed when the bottles were opened (i.e., under normal condition of administration). 
Table 10 shows the contents of COPs in lipofundinR 10% and lipovenöseR  emulsions. In 
lipofundinR 10% emulsion, there was only a slight difference between the concentrations of 
different COPs; however, in lipovenöseR emulsion , the content of cholestantriol was lower. 
 
            Table 10  Concentrations of cholesterol oxidation products in lipid emulsions (ng/ml). 
 
Cholesterol oxidation products         LipofundinR 10%         LipovenöseR   
7α-hydroxycholestrol                216.9             186.6 
7β-hydroxycholestrol                207.5             180.4 
7-ketocholesterol                214.7             123.7 
 3β,5α,6β-cholestantriol               195.3               53.9 
 
6.1.2  COPs in control subjects and in patients receiving lipofundinR 10%  
Table 11 summarizes the concentrations of COPs in the serum of six healthy volunteers (two 
males and four females), as well as in patients receiving parenteral nutrition with lipid emulsion 
(n=9). As can be seen, a wide range of COP concentrations was recorded, especially for the 
typical non-enzymatic COPs (although the concentrations of 7α-hydroxycholesterol were  
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expected to vary widely because they reflect the cholesterol 7α-hydroxylase activity in the liver). 
Cholesterol non-enzymatic oxidation products, such as 7β-hydroxycholesterol and  
7-ketocholesterol were not expected to show such great variation.  
Table 11  Concentrations of COPs in serum from control subjects and patients receiving 
lipofundinR 10%   emulsion (ng/ml). 
 
     
 7α-hydroxy-   
 cholesterol 
 
              
    
  7β-hydroxy- 
  cholesterol 
 
                     
   
   7-Keto- 
   cholesterol 
 
     
  
 3β,5α,6β-    
cholestantriol 
 
 
Sample no.        A B        A B        A B        A B 
      1      69.8 16.9       20.7   9.0    165.3 30.8     91.8 18.7 
      2      28.5 12.5         4.3   6.5      17.4 22.9       5.6 10.4 
      3      23.0 12.4         5.5   5.3      18.6 19.7       4.1   6.1 
      4      46.0 5.6       24.5   6.3      52.0 17.1     35.8   1.8 
      5      39.3 13.3         3.5 14.8      10.4 42.0       2.6   8.5 
      6      19.0 13.9       36.4   8.4      84.9 16.1     11.6   5.3 
      7  29.0    8.8  21.0    4.6 
      8    7.3    6.3  22.5    1.9 
      9    9.5    8.5  19.8    8.1 
  Mean      37.6 13.4       15.8   8.2      58.1 23.5      25.2   7.3 
  SD      18.7   6.8       13.5   2.8      59.6 8.1        34.9   5.2 
A = healthy volunteer;   B = patients under lipid emulsion infusion 
 
6.1.3  COPs in the serum from sitosterolemic patients 
6.1.3.1  COPs in the serum from sitosterolemic patients treated with resins and  resins plus 
             ezetimibe 
Three patients were treated with bile acid binding resins and for eight weeks with ezetimibe (see 
Table 12). The patients showed no significant difference in the concentrations of oxycholesterols 
before and after ezetimibe treatment. As expected, in patients treated with bile acid binding 
resins, 7α-hydroxycholesterol and other oxycholesterols were higher compared with those treated 
with statins. The addition of ezetimibe to bile acid binding resins had no significant effect on the 
concentrations of oxycholesterols as the P values of t test were > 0.05 . 
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Table 12  Concentrations of  COPs in serum of 3 patients with sitosterolemia treated with resins 
and resins plus  ezetimibe (ng/ml). 
 
     
 7α-hydroxy-   
 cholesterol 
 
              
    
  7β-hydroxy- 
  cholesterol 
 
                     
   
   7-Keto- 
   cholesterol 
 
     
  
 3β,5α,6β- 
cholestantriol 
 
 
Patient       A B       A B       A B       A B 
      1    253.9   87.1 158.1 107.8 361.9 263.9     100.8 85.1 
      2    494.1 400.7 399.8 436.5 607.7 758.4     164.6 82.5 
      3    173.3 134.8   38.0   25.8   39.8   14.0       10.5 26.5 
  Mean    307.1 207.5 198.6 190.1 336.5 345.4       92.0 64.7 
  SD    166.9 169.0   184.3 217.4   284.8 378.9       77.5 33.1 
P value           0.508          0.959          0.974            0.608 
A = bile acid binding resins; B = bile acid binding resins plus ezetimibe 
 
   
 
6.1.3.2  COPs in the serum from sitosterolemic patients treated with statins and statins plus 
             ezetimibe 
Combined treatment with statins and ezetimibe for eight weeks in patients with sitosterolemia 
(n=4) produced no difference in the concentration of COPs, indicating that ezetimibe has no 
effect. These results can be seen in Table 13. T test was used, where the statistical P values of the 
different oxycholesterols were > 0.05. 
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Table 13  Concentrations of COPs in serum of 4 patients with sitosterolemia treated with statins 
and statins plus ezetimibe (ng/ml).   
     
     
 7α-hydroxy-   
 cholesterol 
 
              
    
  7β-hydroxy- 
  cholesterol 
 
                     
   
   7-Keto- 
   cholesterol 
 
     
  
 3β,5α,6β- 
cholestantriol 
 
 
Patient        A   B       A  B       A   B        A   B 
      1      68.8   82.1      35.2 131.0      31.5 110.0       33.0 36.2 
      2      53.5   47.5      49.1   42.8      39.9   37.1       17.7 20.8 
      3    146.7 175.7      61.6 107.0      79.8 106.1       20.6 26.2 
      4    128.6   85.9    147.9   70.5    179.8 103.3       49.7 46.7 
  Mean      99.4   97.8     73.5   87.8     82.7   89.1       30.2 32.5 
  SD      45.3   54.7     50.8     39.0    68.0   34.8       14.6 11.5 
P value            0.968            0.666            0.861             0.816        
A = statins; B = statins plus ezetimibe 
 
6.1.3.3  COPs in sitosterolemic patients treated with ezetimibe only 
Although ezetimibe showed a significant cholesterol-reducing effect in hypercholesterolemic 
patients (11), ezetimibe did not produce any effect on the COP concentrations in sitosterolemic 
patients (see Table 14), as the calculated P values of t test for oxycholesterols showed no 
significant difference (P > 0.05). 
 
Table 14  Concentrations of  COPs in serum of 6 sittosterolemic patients treated with ezetimibe 
only (ng/ml). 
 
     
 7α-hydroxy-   
 cholesterol 
 
              
    
  7β-hydroxy- 
  cholesterol 
 
                     
   
   7-Keto- 
   cholesterol 
 
     
  
 3β,5α,6β-
cholestantriol 
 
 
Patient        A B        A B        A B        A B 
      1      56.8   57.1      20.5   32.6      22.0   27.9      33.0 29.8 
      2      53.7   55.4      29.9 132.0      41.7 212.4      66.7 88.6 
      3      90.8   43.9    126.6   54.1    119.6   47.9      50.7 39.7 
      4      62.6   64.1      64.8   95.5    144.1 138.4      66.5 46.9 
      5    264.8 354.6      39.3   62.2      53.3 113.9      17.5 23.0 
      6    137.8   76.3      19.4   54.3      20.5   63.0      17.5 22.1 
  Mean    108.1 108.0      50.1   71.8      66.9 100.6      42.0 41.7 
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  SD      81.6 121.0      41.0   35.9      52.4   68.7      22.7 24.9 
P value            0.972           0.348            0.365            0.981 
A = patients without treatment; B = patients treated only with ezetimibe 
 
6.2  Phytosterol oxidation products (POPs)  
6.2.1  POPs in lipid emulsions used as parenteral nutrition 
The presence of POPs in lipid emulsions used for intravenous nutrition was first confirmed by 
Plat et al. (9). In the present study, the contents of oxidized sitosterol and campesterol are 
summarized in Tables 15a and 15b, where it can be seen that 7-ketositosterol and 7-
ketocampesterol are present in both emulsions in higher concentrations than the other sitosterol 
and campesterol oxidation products. However, the concentrations of all campesterol oxidation 
products are lower than those of sitosterol oxidation products, except in the case of 
campestantriol. 
 
 
            Table 15a  Concentrations of sitosterol oxidation products in lipid emulsions (ng/ml). 
 
Sitosterol oxidation products        lipofundinR 10%           LipovenöseR   
7α-Hydroxysitosterol                14.5                 10.3 
7β-Hydroxysitosterol                28.0                 21.7 
7-Ketositosterol              184.5               177.5 
3β,5α,6β-sitostantriol                20.8                 13.2 
 
 
            Table 15b  Concentraions of campesterol oxidation products in lipid emulsions (ng/ml). 
 
Camptosterol oxidation products    lipofundinR 10%     LipovenöseR   
7α-Hydroxycampesterol                  9.8               6.4 
7β-Hydroxycampesterol                16.3             13.3 
7-Ketocampesterol                75.5             52.7 
3β,5α,6β-campestantriol               22.3             16.1 
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6.2.2  POPs in control subjects and in patients receiving lipofundinR 10% 
Concentration of oxyphytosterols ranged from 8.2  to 92.3 ng/ml serum for oxidized sitosterol 
(see Table 16a) and between 1.8  and  60.2 ng/ml serum for oxycampesterol (see Table 16b). The 
concentrations of oxyphytosterols in patients receiving lipid emulsions were not significantly 
different from the concentrations in normal subjects. The highst concentrations were found for 7-
ketositosterol and 7-ketocampesterol in both healthy subjects and patients receiving lipid 
infusion. 
 
 Table 16a  Concentrations of oxysitosterols in Serum from control subjects and patients 
receiving lipofundinR  10%  (ng/ml). 
  
 
 
    
  
   7α-hydroxy-   
     sitosterol 
 
              
    
   
   7β-hydroxy- 
     sitosterol 
 
                      
                      
   
    
    7-Keto- 
    sitosterol 
 
 
    
  
  
   3β,5α,6β-     
   sitostantriol 
 
 
Sample no.        A B        A B        A B        A B 
      1        9.3 8.7      20.7 20.6      75.9 69.8      16.8 17.5 
      2        8.3 8.7      21.7 19.9      76.8 75.6      13.8 13.8 
      3        8.2 8.3      20.4 19.4      73.2 77.7      12.0 13.1 
      4      15.1 8.5      30.9 18.8      92.3 77.0      24.5 14.2 
      5        8.3 9.9      24.1 22.3      69.1 78.6      14.9 16.6 
      6        9.3 8.4      21.8 20.6      76.9 82.2      17.0 16.4 
      7  9.7  21.0  83.8  15.1 
      8  8.2  21.9  69.6  14.2 
      9  9.1  23.1  79.9  15.5 
  Mean        9.8  8.8      23.3 21.0      77.4 77.1      16.5 15.2 
  SD        2.7  0.6        4.0   1.3        7.9   4.9        4.3   1.5 
A = healthy volunteers; B = patients under lipid emulsion infusion 
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 Table 16b  Concentrations of oxycampesterols in serum from control subjects and patients 
receiving lipofundinR  10%  (ng/ml).    
   
     
 7α-hydroxy-   
  campesterol 
 
 
              
    
  7β-hydroxy- 
   campesterol 
 
 
                     
   
   7-Keto- 
   campesterol 
 
 
 
     
  
 3β,5α,6β-
campestantriol 
 
 
Sample no.         A B        A B        A B        A B 
      1        1.9 2.8      10.4 13.2      48.6 44.4      10.7 10.7 
      2        2.4 2.8      13.6 13.9      49.6 48.8        9.1   9.1 
      3        3.2 2.9      12.6 13.4      48.1 50.8        9.0   8.2 
      4        6.3 2.5      19.0 12.7      60.2 50.3      15.3   9.4 
      5        3.0 2.5      13.4 13.2      44.5 50.2        6.7 10.4 
      6        1.8 2.7      11.9 13.1      48.9 52.8        9.4 21.0 
      7  3.3  14.6  55.2    9.9 
      8  2.4  11.2  46.3    6.8 
      9  2.5  13.3  52.4    9.8 
   Mean        3.1 2.7      13.5 13.2      50.0 50.1      10.0 10.6 
   SD        1.6 0.3        2.9   0.9        5.3   3.3        6.7   4.1 
 A = healthy volunteers; B = patients under lipid emulsion infusion 
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6.2.3  POPs in the serum from sitosterolemic patients 
6.2.3.1  POPs in the serum from sitosterolemic patients treated with resins and resins plus 
             ezetimibe 
Table 17a shows that there was no significant difference in the concentration of oxysitosterols 
before and after the addition of ezetimibe. The same result was found with the concentration of 
oxycampesterols (see Table 17b) as t test was calculated where the P values were > 0.05.  
 
Table 17a  Serum concentrations of oxysitosterols in patients with phytosterolemia treated with    
 resins and resins plus ezetimibe (ng/ml). 
 
     
 7α-hydroxy-   
 sitosterol 
 
              
    
  7β-hydroxy- 
  sitosterol 
 
                     
   
   7-Keto- 
   sitosterol 
 
     
  
 3β,5α,6β- 
sitostantriol 
 
 
Patient        A   B      A  B       A   B       A   B 
      1      21.8 15.6      48.6 37.2    153.4 121.5       17.4 15.6 
      2      10.2 11.4      31.5 42.0    110.7 108.4       14.8 13.2 
      3      12.1 9.8      28.7 24.4      70.8   69.5       14.7 14.2 
  Mean      14.7 12.3      36.3 34.5    111.6   99.8       15.6 14.3 
  SD        6.3   2.9     10.7   9.1     41.3   27.0         1.5   1.2 
P value            0.523            0.879           0.704           0.435 
    
 
Table 17b  Serum concentrations of oxycampesterols in patients with phytosterolemia treated  
with resins and resins plus ezetimibe (ng/ml). 
 
     
 7α-hydroxy-   
 campesterol 
 
              
    
  7β-hydroxy- 
  campesterol 
 
                     
   
   7-Keto- 
   campesterol 
 
     
  
 3β,5α,6β- 
campestantriol 
 
 
Patient        A   B      A  B       A   B       A   B 
      1        4.1   1.6      17.7 14.7      79.8 67.7       15.7 12.7 
      2        3.6   3.4      13.1 11.3      64.1 65.2       13.1 10.7 
      3        3.2   3.4      14.0 13.4      44.2 41.5       11.0 11.6 
  Mean        3.6   2.8      14.9 13.1      62.7 58.1       13.3 11.7 
  SD        0.4   1.0       2.5   1.7     17.8 14.5         2.3   1.0 
P value           0.251            0.250           0.740            0.196 
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For Tables 17a and 17b; A = bile acid binding resins; B = bile acid binding resins plus ezetimibe 
 
6.2.3.2  POPs in the serum from sitosterolemic patients treated with statins and statins plus  
             ezetimibe 
Addition of ezetimibe to statin treatment did not result in any significant effect on the 
concentrations of oxysitosterols in sitosterolemic patients (see Table 18a). There is also no 
difference between the concentrations of oxycampesterol before and after ezetimibe treatment 
(see Table 18b) as the P values of t test were > 0.05.  
   
Table 18a  Serum concentrations of oxysitosterols in sitosterolemic patients treated with statins 
and statins plus ezeimibe (ng/ml). 
  
     
    7α-hydroxy-   
     sitosterol 
 
              
    
     7β-hydroxy- 
      sitosterol 
 
                     
   
      7-Keto- 
     sitosterol 
 
     
  
    3β,5α,6β- 
   sitostantriol 
 
 
Patient        A   B      A  B       A   B       A   B 
      1      14.6 22.4      42.4 57.3      86.2 92.1       19.4 20.0 
      2      12.7 13.6      31.8 29.8      71.1 70.5       14.4 17.5 
      3      15.6 20.4      37.6 43.1      85.4 88.5       16.5 17.0 
      4      24.6 12.6      51.6 34.9      92.2 82.3       18.9 16.4 
  Mean      16.9 17.3      40.9 41.3      83.7 83.4       17.3 17.7 
  SD        5.3   4.9       8.4 12.0       9.0   9.5         2.3   1.6 
P value            0.895            0.949            0.942            0.613 
 
 
Table 18b  serum concentrations of oxycampesterols in sitosterolemic patients treated with statins 
and with statins  plus ezetimibe (ng/ml). 
 
     
   7α-hydroxy-   
    campesterol 
 
              
    
    7β-hydroxy- 
    campesterol 
 
                     
   
      7-Keto- 
     campesterol 
 
     
  
    3β,5α,6β- 
  campestantriol 
 
 
Patient        A   B      A  B       A   B       A   B 
      1        4.4 8.5      19.1 28.5      54.3 60.9       18.7 17.4 
      2        4.7 4.1      17.1 17.5      45.3 44.2         8.9 11.6 
      3        5.4 8.6      20.8 27.0      54.1 54.0       11.8 12.5 
      4        6.5 2.0      25.4 16.9      58.7 50.9       12.9 11.1 
  Mean        5.2 5.8      20.6 22.5      53.1 52.5       13.1 13.2 
  SD        0.9 3.3       3.5   6.1       5.6   6.9         4.1   2.9 
P value           0.651            0.645            0.869            0.851 
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For Tables 18a and 18b:  A = statins; B = statins plus ezetimibe 
 
          
6.2.3.3  POPs in the serum from sitosterolemic patients treated with ezetimibe only 
Statistical analysis by t-test for dependent variables showed no significant difference in the 
concentration of either oxysitosterol or oxycampesterol in sitosterolemic patients before and after 
treatment with ezetimibe, as P > 0.05 (see Tables 19a and 19b). 
 
Table 19a  Serum concentrations of oxysitosterols in sitosterolemic patients treated with 
ezetimibe only (ng/ml). 
 
     
    7α-hydroxy-   
     sitosterol 
 
              
    
    7β-hydroxy- 
     sitosterol 
 
                     
   
     7-Keto- 
     sitosterol 
 
     
  
3β,5α,6β-     
   sitostantriol 
 
 
Patient        A B        A B       A B        A B 
      1      11.4 10.9      26.7 24.8      76.2 72.3      17.2 14.6 
      2      11.9 13.6      30.2 29.8      75.4 84.3      16.5 15.8 
      3      18.1 11.2      42.1 24.0      86.4 76.7      15.9 15.3 
      4      11.3 10.9      25.9 25.6      70.7 73.6      15.7 14.9 
      5      10.4 10.5      24.6 24.6      68.2 73.3      15.5 16.1 
      6      11.1 14.4      29.0 40.5      79.4 81.6      15.5 15.6 
  Mean      11.9 11.9      29.7 28.2      76.1 77.0      16.1 15.4 
  SD        2.9   1.7        6.4   6.4        6.5   5.0        0.7   0.5 
P value            0.646            0.666            0.807            0.177 
 
 
Table 19b  Serum concentrations of oxycampesterols in sitosterolemic patients treated with 
ezetimibe only (ng/ml).         
       
     
    7α-hydroxy-   
   campesterol 
 
              
    
     7β-hydroxy- 
    campesterol 
 
                     
   
       7-Keto- 
     campesterol 
 
     
  
    3β,5α,6β-   
  campestantriol 
 
 
Patient         A B       A B      A B       A B 
      1        2.5   3.5      13.6 14.1      44.3 44.7      11.4 11.6 
      2        3.7 17.3      14.9 15.1      47.8 54.6      15.2 13.0 
      3        4.9   2.5      20.3 13.8      51.1 49.6      11.8   9.9 
      4        2.8   2.0      14.0 15.2      41.8 47.4      10.7   9.7 
      5        2.4   1.4      12.9 13.2      44.9 48.3      11.8 11.3 
      6        4.8   5.0      14.7 19.2      49.6 52.0      14.7 14.4 
Mean        3.5   5.3      15.1 15.1      46.6 49.4      12.6 11.7 
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SD        1.1   6.0        2.7   2.2        3.5   3.5        1.9   1.9 
P value             0.406            0.825            0.183             0.491 
 For Tables 19a and 19b;   A= patients without treatment; B = patients treated only with ezetimibe 
B. Results of the second study  
6.3  Cholesterol 
Table 20 show the concentrations of cholesterol in the serum of sitosterolemic patients receiving 
different drug treatments. The Anderson-Darling test reveals that the data samples were normally 
distributed. By using the ANOVA test, it could be concluded that the different drug treatments 
have no significant effect, as  P= 0.209 . 
 
Table 20  Cholesterol concentrations in the serum of sitosterolemic patients under different  
drug treatments (mg/dl). 
 
      Patients 
without 
      treatment 
  Patients with    
       statins 
 Patients with 
       resins 
  Patients with 
 statins + resins 
          1         122         238         141         117 
          2         140         147         162         210 
          3         171         195         177           96 
          4         339         182         123         161 
          5         168         143         171   
          6         176         145           96   
          7         244         238           98   
          8         113          158   
          9           92          134   
        10         205          103   
      Mean 
      SD 
        177 
          72.5 
        184  
          41.9           
        136 
          30.5 
        146 
          50.5 
 
6.4  Lathosterol 
Since lathosterol is a precursor for cholesterol biosynthesis, the level of this parameter in the 
serum of patients with sitosterolemia could be used as an index for the effect(s) of different drug 
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treatments on cholesterol biosynthesis. The data samples shown in Table 21 were not normally 
distributed; therefore non-parametric tests were used. 
The Kruskal-Wallis test revealed the significant difference between the control group and the 
other groups under different drug treatments as P = 0.006. By using the Mann-Whitney test, we 
could determine where these significant changes exist, as P ≤ 0.05. These changes were between 
1) the group treated with resins and the control group; 2) the group undergoing combined therapy 
(statins plus resins) and the control group; 3) the statins group and the resins group; and 4) the 
group undergoing combined therapy and the resins group. 
 
Table 21  Lathosterol concentrations in the serum of sitosterolemic patients under different  
drug treatments (mg/dl). 
 
    Patients without 
     treatment       
Patients with 
     statins 
  Patients with 
       resins 
 Patients with 
 statins + resins 
          1          0.087       0.112          0.422        0.056 
          2          0.194       0.092          0.259        0.070 
          3          0.159       0.154          0.230        0.088 
          4          0.279       0.352          0.714        0.098 
          5          0.178       0.170          1.410  
          6          0.09       0.060          0.318  
          7          0.105       0.106          0.331  
          8          0.947           0.067  
          9          0.218           0.249  
        10          0.244           1.352  
       Mean 
       SD 
         0.25 
         0.25 
      0.15 
      0.10 
         0.535  
         0.53  
        0.078 
        0.02 
 
 
6.5  Plant sterols  
The following tables (Tables 22, 23, 24 and 25) show the concentrations of plant sterols in the 
serum of sitosterolemic patients treated with different drugs. The Anderson-Darling test showed 
that the data samples for campesterol, sitosterol and sitostanol were normally distributed, as P > 
0.05. The data samples were analyzed parametrically using the ANOVA test, but did not reveal 
any significant difference among the various groups for any of the above-mentioned plant sterols, 
as P values were more than 0.05. 
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In the case of campestanol, the P value of the Anderson–Darling test was less than 0.05, meaning 
that the sample data was not normally distributed. It could be analyzed non-parametrically by 
using the Mann-Whitney test, which indicated that a difference existed between the group treated 
with statins and the group treated with resins.    
 
 
 
Table 22  Campesterol concentrations in the serum of sitosterolemic patients under different  
drug treatment (mg/dl). 
 
      Patients 
without 
      treatment 
  Patients with 
      statins 
  Patients with 
        resins 
 Patients with  
 statins + resins 
          1          2.286       12.267          6.912         8.401 
          2        13.049         9.141          7.055       13.230 
          3        11.934       12.436        14.523       12.259 
          4        14.898       12.891        13.211         9.574 
          5          9.354       15.433          5.956  
          6          5.905       12.348        16.497  
          7        20.956       28.503          4.267  
          8          3.642         11.086  
          9          6.185           8.227  
        10          9.534           3.831  
       Mean 
       SD 
         9.774 
         5.66          
       14.717 
         6.34 
         9.156 
         4.41 
      10.866 
        2.25 
 
 
 
 Table 23  Campestanol concentrations in the serum of sitosterolemic patients under different 
 drug treatment (mg/dl). 
 
     Patients without 
    treatment 
  Patients with 
      statins 
  Patients with 
        resins 
 Patients with 
statins + resins 
          1          0.725       4.035         0.914       3.044 
          2          2.746       2.182         1.870       1.764 
          3          2.587       2.782         3.364       2.876 
          4          4.155       2.756         2.438       2.597 
          5          3.324       3.717         1.172  
          6          2.006       3.458         2.144  
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          7          4.872       8.525         1.197  
          8          0.818          3.450  
          9          1.997          2.155  
        10          2.237          0.994  
       Mean 
       SD 
         2.547 
         1.32 
     3.922 
     2.13 
        1.97 
        0.93 
       2.57 
       0.57 
 
 
 
 
 
Table 24  Sitosterol concentrations in the serum of sitosterolemic patients under different  
drug treatment (mg/dl). 
 
  Patients without 
     treatment 
 Patients with  
      statins 
  Patients with 
        resins 
 Patients with  
statins + resins 
          1         5.629       23.466        14.576       18.802 
          2       27.591       18.102        18.294       26.541 
          3       31.230       20.771        25.103       16.622 
          4       34.729       20.698        28.619       19.519 
          5       19.708       28.293        11.182  
          6       15.216       20.309        24.189  
          7       28.797       43.511        15.364  
          8         9.783         21.064  
          9       12.007         15.303  
        10       21.795         11.449  
       Mean 
       SD 
      20.649 
        9.86 
       25.021 
         8.77 
       18.514 
         5.99  
      20.371 
        4.29           
 
 
 
Table 25  Sitostanol concentrations in the serum of sitosterolemic patients under different  
drug treatment (mg/dl).  
 
    Patients without  
     treatment 
  Patients with 
      statins 
  Patients with 
        resins 
  Patients with 
 statins + resins 
          1         1.294        8.691         2.520        7.833 
          2         7.173        5.736         5.193        5.734 
          3         7.055        6.123         7.298        6.584 
          4       10.064        6.596         7.028        6.852 
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          5         7.804        9.347         3.600  
          6         5.328        7.343         4.355  
          7         8.502      15.464         5.234  
          8         2.976          6.713  
          9         5.021          5.408  
        10         5.918          3.773  
       Mean 
       SD 
        6.114 
        2.60 
       8.471 
       3.35 
        5.112 
        1.58 
        6.751 
        0.86 
6.6  Lathosterol/cholesterol ratio 
The ratio of lathosterol to cholesterol can be used as an index of cholesterol biosynthesis (see also 
6.4). Table 26 showed that the highest ratio was in the patient group treated with resins only 
(4.19), and the lowest ratio was with the patients under statins plus resins treatment (0.58).   
 
Table 26  The ratio of lathosterol to cholesterol concentrations in the serum of sitosterolemic 
patients under different drug treatments (µg/mg). 
 
     Patients without  
     treatment 
  Patients with 
       statins 
  Patients with  
       resins 
 Patients with  
statins + resins 
          1         0.711         0.471         2.988         0.478 
          2         1.388         0.629         1.600         0.333 
          3         0.932         0.789         1.306         0.920 
          4         0.821         1.929         5.790         0.607 
          5         1.061         1.185         8.228  
          6         0.512         0.417         3.306  
          7         0.430         0.445         3.362  
          8         8.405          0.427  
          9         2.372          1.852  
        10         1.190        13.122  
       Mean 
       SD 
        1.782 
        2.39 
       0.838 
       0.55 
        4.198 
        3.89 
        0.584 
        0.25 
 
6.7  Campesterol/cholesterol ratio 
The ratio of campesterol to cholesterol is an indicator for cholesterol and plant sterols absorption. 
As can be seen in Table 27, it was found that the highest ratio was in case of statins as  a 
monotherapy (80.11) or as a daul therapy (80.45). 
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Table 27  The ratio of campesterol to cholesterol concentrations in the serum of sitosterolemic 
patients under different drug treatment (µg/mg). 
 
   Patients without 
    treatment 
  Patients with 
      statins 
  Patients with 
      resins 
  Patients with  
 statins + resins 
          1        18.66         51.60       48.96       71.94 
          2        93.30         62.17       43.55       62.87 
          3        69.98         63.63       82.26     127.48 
          4        43.89         70.67     107.17       59.52 
          5        55.75       107.87       34.76  
          6        33.48         85.17     171.60  
          7        85.91       119.67       43.39  
          8        32.32        70.25  
          9        67.23        61.23  
        10        46.48        37.19  
       Mean 
       SD 
       54.70 
       24.24 
        80.11 
        25.35 
      70.04 
      42.29 
      80.45 
      31.78 
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7   Discussion   
The relationship between COPs and atherosclerosis has been widely studied. Most information 
about their possible atherogenicity is derived from in vitro studies showing that COPs are 
cytotoxic (91). While no direct evidence of a connection between COPs and atherosclerosis in 
humans has been established, several findings suggest that such a connection exists. On the other 
hand, few studies have measured the biological effects of POPs, although some researchers have 
shown their cytotoxic effects (54, 55). Feeding LDL receptor-deficient and apolipoprotein E-
deficient mice a mixture of COPs accelerated fatty streak lesion formation (92); however, 
exogenous oxyphytosterols were well absorbed and accumulated in the body, but did not promote 
the development of atherosclerosis in apolipoprotein E-deficient mice (93).  
Determination of low concentrations of COPs in biological samples which may contain more 
than 1,000 times as much cholesterol as COPs is difficult because of the interference with 
cholesterol. It is important to be aware of this problem when determining concentrations of the 
common COPs, such as 7α-,7β-hydroxycholesterol and 7-ketocholesterol. In earlier research, 
very high concentrations of COPs were sometimes reported, probably reflecting significant 
autoxidation of cholesterol during the sample work-up. As analytical techniques have improved, 
the reported concentrations of these products have tended to decline.  
COPs in living tissues originate from the diet and from non-enzymatic or enzymatic cholesterol 
oxidation. For example, 7α-hydroxycholesterol is formed from cholesterol by the hepatic enzyme 
cholesterol 7α-hydroxylase as a normal intermediate in bile acid biosynthesis. In addition, 7α-
hydroxycholesterol is formed by autoxidation, if the samples are not protected from oxygen. The 
presence of dietary COPs in the circulation depends on the rate of absorption from the gut, their 
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transport to the specific tissue and their elimination, whereas formation of COPs from 
endogenous cholesterol depends on substrate availability, activity of cholesterol-metabolizing 
enzymes and the degree of oxidative stress. However, it is difficult to distinguish between 
oxycholesterols derived from the diet and those endogenously formed. 
Little information is available on the presence of  POPs in food. Research with rats has shown 
that some oxyphytosterols were absorbed from the diet and incorporated into mesenteric lymph 
(57). Extensive information about endogenous formation of oxyphytosterols, whether 
enzymatically or nonenzymatically, is also lacking. Since it was recently discovered that 
oxyphytosterols showed similar cytotoxic effects to those caused by oxycholesterols on cultured 
macrophages (59), we should expand our knowledge concerning the presence of oxyphytosterols 
in biological materials. 
Sitosterolemia is a rare, autosomal recessively inherited sterol-storage disease characterized 
clinically by premature atherosclerosis and early cardiovascular death and biochemically by 
increased levels of plant sterols (sitosterol, campesterol, stigmasterol and other phytosterols) and 
their 5α-stanol derivatives in plasma and other tissues. Sitosterolemia has been shown to be due 
to mutations in either of the two ATP-binding cassette (ABC) transporters, ABCG5 or ABCG8 
(10, 63 and 64). Plat et al. (9) found some oxysitosterols (7-keto, 7β-hydroxy, 5α, 6α-epoxy, and 
3β, 5α, 6β-tri-hydroxy sitosterol), in addition to plant sterols, in the plasma of sitosterolemic 
patients. In this work we were also able to identify 7α-hydroxy, 7β-hydroxy, 7-keto, and 3β, 5α, 
6β-tri-hydroxysitosterol/campesterol in sitosterolemic patients, as well as in normal healthy 
volunteers. The presence of oxidized derivatives of phytosterols in plasma from thirteen normal 
subjects was also confirmed by Grandgirard et al. (51). 
At present, most analytical methods used to study both oxycholesterols and oxyphytosterols are 
based on GC with flame ionization detection (FID) or GC-MS with selected ion monitoring 
(SIM). The great advantage of SIM over FID is the specificity of  detection, which is necessary 
for the analysis of oxysterols in complex biological matrices. The choice of GC-MS with multiple 
deuterium-labelled internal standards, as in the present study, is preferable, because this method 
is sensitive and specific for the different analytes. 
In using this method, the internal standard for each COP was the corresponding multideuterium-
labelled COP; thus the behavior of the analytes and the internal standards during the work-up of 
the samples was similar. This corrected the differences in the recovery of the original 
compounds. The principles of this method are alkaline hydrolysis (saponification), solid-phase 
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extraction and GC-MS measurement. A drawback of the method is the relatively laborious 
sample work-up, which limits the number of samples that can be processed simultaneously. In 
addition, the synthesis of internal standards is very laborious and expensive. 
The principles of analysis for POPs are not different from those for COPs, i.e., saponification, 
extraction of lipids, enrichment of POPs and subsequent qualitative and quantitative 
determination by GC-MS. Very few publications on the analysis of POPs are available at this 
time, and a negligible amount of research has been carried out on their biological effects. This 
will almost inevitably lead to difficulties in comparing our work with other studies. 
To analyze oxidized cholesterol and oxidized plant sterol products in human plasma, we used the 
GC-MS method first developed by Dezletovic et al. (88). The alkaline hydrolysis parameters 
chosen were 0.35 M of KOH at 22°C for two hours, where with this protocol 91-94% of the 
cholesterol esters were hydrolyzed. The solid-phase extraction step was modified by using 10 ml 
0.25% isopropanol-cyclohexane (v/v) instead of 8 ml 0.5% isopropanol-hexane (v/v) to elute 
neutral sterols, and 8 ml 30% isopropanol-cyclohexane instead of 5 ml 30% isopropanol in 
hexane to elute oxysterols. All possible precautions were taken to reduce undesired autoxidation 
of cholesterol and plant sterols during the sample work-up. Precautions included keeping the 
serum samples at -80°C with BHT (25 mg/ml methanol) and saturating them extensively with 
argon during the work-up. In addition, a carefully controlled alkaline hydrolysis process and 
rapid separation of neutral sterols from oxycholesterols and oxyphytosterols were carried out. 
The mass spectrometer was operated in the selected ion-monitoring mode, where the ion used for 
analysis (m/z) and the typical retention time (in minutes) for each deuterated and non-deuterated 
compound offer the advantage of specificity of detection. 
Recovery experiments were performed on spiked serum samples by addition of different volumes 
of a standard mixture of oxycholesterols and oxyphytosterols. As shown in Table 7c (see page 
45),  recovery ranged from 82% in case of cholestantriol to 123% in case of 7-ketositosterol, 
indicating that satisfactory recoveries were obtained for all compounds. Table 8 (see page 46) 
represents the intra-assay precision, also termed as repeatability. Detection limit in this work was 
calculated by using the signal-to-noise ratios method. Here the limits of detection were lower 
than 1 ng/ml, except in case of 7-ketositosterol (5.91 ng/ml) and 7-ketocampesterol (2.22 ng/ml).  
The linearity of the GC-MS responses was evaluated by analyzing standard mixtures of 
oxycholesterols and oxyphytosterols using the same procedure as described for the serum 
samples, with the regression coefficient of the standard curves ranging from 0.992 for 
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sitostantriol to 0.9998 for 7α-hydroxycholesterol. The linear range of all compounds was 
calculated using the correlation coefficient, y-intercept and response factor of the regression line, 
except in case of 7-ketositosterol and 7-ketocampesterol. For these two compounds, the 
concentrations were calculated using polynomic curves, which yielded the correlation coefficient 
better than a linear calibration curve.  
In this work we examined the possibility that cholesterol and plant sterol oxidation products were 
present in two commercially available lipid emulsions that are used as parenteral nutrition. 
Various oxycholesterols and oxyphytosterols were detected in the emulsions (see Tables 10, 15a 
and 15b, pages 50 and 55), but the concentrations were lower than those found by Plat et al. (see 
Table 3, page 35). According to our results, the concentrations of  oxyphytosterols in emulsion 
LipofundinR 10%  were higher than in emulsion LipovenösR ; in addition, the concentrations of 
oxysitosterols were always more than those of oxycampesterols, only the concentration of 
campestantriol which was more than sitostantriol. Whether these oxidized compounds have 
biological or pathological effects on patients receiving intravenous lipid emulsions, especially 
infants, requires further investigation. 
The presence of oxycholesterols and oxyphytosterols in serum from normal subjects was 
demonstrated in this study as well as in research by Grandgirard et al. (51); it is important, 
however, to note that Grandgirard et al. used a different internal standard. These oxidized 
compounds were also found in the serum of patients receiving lipid emulsions. Although these 
lipid emulsions contain high amounts of oxidized cholesterol and oxidized plant sterols, we found 
that the concentrations of oxycholesterols in normal subjects were higher than in patients 
receiving lipid nutrition; the amounts of oxysitosterols and oxycampesterols for these patients 
were not different from amounts found in normal subjects. An important note is that we did not 
investigate the presence of these compounds in those patients before introduction of lipid 
emulsions. Optimal research design would include measuring the concentration of these oxidized 
compounds before and after intravenous lipid emulsion introduction. 
 There is unfortunately very little information available on oxysterols, their absorption and their 
biological effects in humans. No research has investigated the effects of drug treatment on the 
level of these compounds in blood serum, whether in normal subjects or in sitosterolemic 
patients. The intestinal absorption of sterols is still not fully understood, but with the 
identification of the role of ABCG5 and ABCG8 transporters (10, 63), the introduction of 
ezetimibe as the first cholesterol absorption inhibitor and the identification of the NPC1L1 
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protein as a sterol transporter (17), more details about sterol transport processes in the small 
intestine have become available. 
This research aimed to examine the effect of ezetimibe on the concentrations of oxycholesterols 
and oxyphytosterols in serum from sitosterolemic patients undergoing treatment with bile acid 
binding resins and/or statins and and in patients who were not receiving any drug treatment. 
Ezetimibe is a novel inhibitor of intestinal cholesterol absorption in humans, shown to 
significantly lower plasma cholesterol and LDL-C concentrations in patients with 
hypercholesterolemia (11). Similarly, in patients with sitosterolemia, ezetimibe also produced a 
significant and progressive reduction in plasma plant sterol concentrations during short-term 
treatment (12). In contrast, however, to its effect on neutral sterols, ezetimibe did not decrease the 
concentrations of oxidized sterols in the blood of sitosterolemic patients.  
In looking at the results of this present work (presented in Tables 12, 13, 14, 17a, 17b, 18a, 
18b,19a and 19b), we can conclude that ezetimibe probably has no effect on the levels of 
oxycholesterols, oxysitosterols and oxycampesterols, since the mean values before and after 
ezetimibe introduction were almost the same except in the case of 7α-hydroxycholesterol and 
cholestantriol, where it seems that ezetimibe slightly decreased the concentration of these two 
oxycholesterols in patients being treated with bile acid binding resins. A T-test also showed no 
effect of ezetimibe on the levels of oxycholesterols, as P values were above 0.05, which was 
taken as significanc level. 
It is difficult to explain why ezetimibe has no effect on the level of oxysterols in serum from 
sitosterolemic patients that is similar to its effect in reducing normal sterols (11, 12). One 
possible explanation of why ezetimibe has no effect on oxysterols in sitosterolemic patients is the 
following: the treatment with ezetimibe lasted only for eight weeks, and the half-life of oxysterols 
is not known. We need to expand our knowledge of the mechanisms of intestinal oxysterol 
absorption and further investigate the mechanisms underlying ezetimibe’s effects. Future studies 
should involve larger sample sizes; in this work the number of samples was very limited. 
In order to study the effect of different drug treatments on the serum level of cholesterol and plant 
sterols, serum samples were taken from 31 sitosterolemic patients and analyzed using the GC 
method, where 5α-cholestane was added as internal standard. Cholesterol, lathosterol, plant 
sterols and plant stanols were analyzed in those patients, who were divided into four groups, as 
described above. 
Generally, normal to moderately elevated plasma levels of cholesterol were observed in the 
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patients with sitosterolemia. In this work, the different treatments with bile acids binding resins 
or with statins as a monotherapy or as a combined therapy did not produce any statistically 
significant change, although the level of cholesterol under resins treatment was the lowest  
(136 mg/dl). 
Lathosterol, a precursor for cholesterol biosynthesis, was increased in the case of patients who 
were under bile acids binding resins (0.535 mg/dl) and decreased in those who were on statins as 
a dual treatment with resins (0.078 mg/dl) or as a monotherapy (0.150 mg/dl). These changes 
could be confirmed statistically by non-parametric analysis where P values showed a significant 
difference between the four groups. The increasing level of lathosterol in those patients treated 
with resins is due to interruption of bile acids reabsorption, resulting in increased synthesis of 
cholesterol in the liver and a decrease in cholesterol plasma level by increased expression of LDL 
receptors. This could be confirmed by calculating the lathosterol-to-cholesterol ratio, which is an 
index to cholesterol biosynthesis. Here the higher ratio was in those treated with resins (4.19) and 
the lower ratios were in the group undergoing combined therapy (0.584) and in those treated with 
statins (0.838).  
Statins, HMG-CoA reductase inhibitors, are the most effective drugs in the treatment of 
hypercholesterolemia, due to their inhibition of the activity of HMG-CoA reductase, the rate-
limiting enzyme in the cholesterol biosynthesis process. This inhibition results in increased 
expression of LDL receptors, which lowers serum LDL-cholesterol levels. 
If we compare the effect of statins on the cholesterol level in hypercholesterolemic patients and 
their effects on plant sterols in sitosterolemic patients, we find that statins do not reduce plasma 
plant sterols and stanols. We found in this work that the levels of plant sterols (sitosterol and 
campesterol) and stanols (sitostanol and campestanol) were increased in the group of patients 
under statins treatment (see Tables 22, 23, 24 and 25, pages 64-65). This is likely due to 
decreased biliary cholesterol secretion, which leads to an increased proportion of dietary plant 
sterols in the intestinal sterol pool, thus favoring their increased absorption. Increased absorption 
and reduced biliary secretion may increase the serum level of plant sterols during statin treatment. 
This finding could be confirmed by calculating the campesterol-to-cholesterol concentration 
ratio, as an indicator of sterol absorption, where the higher ratio was in fact found in the statins 
group (80,11). This fits in with the conclusions drawn by Miettinen et al. (94).  
In comparing dual therapy using resins plus statins with monotherapy using resins alone, there 
was no significant difference found in the level of sterols and cholesterol. Therefore, this type of 
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combined therapy is not necessary to decrease the level of sterols in sitosterolemic patients, a 
finding in agreement with the observations of Cobb et al. (95). The question of whether a 
combined therapy of ezetimibe plus resins is superior to ezetimibe alone for treatment of  
sitosterolemia requires further investigation. 
In conclusion, ezetimibe did not produce any significant reduction in plasma oxysterols 
concentrations in patients with sitosterolemia. These oxysterols could be also found in normal 
subjects and also in two frequently used lipid emulsions. Before ezetimibe introduction, bile acids 
binding resins were the best drugs used to decrease the plasma level of cholesterol and plant 
sterols in patients with sitosterolemia as statins were not effective. 
8   Summary 
Oxycholesterols and oxyphytosterols (oxysterols) are oxidized compounds produced either in 
vitro or in vivo by oxidation of cholesterol and plant sterols, respectively. They may have 
implications in the etiology of atherosclerosis.  
 
Sitosterolemia is a very rare inherited disorder, characterized biochemically by elevated plasma 
levels of the major plant sterols and clinically by the presence of tendon and tuberous xanthomas 
and by a strong predisposition to premature coronary artery disease, but with normal to 
moderately elevated plasma cholesterol levels. The genetic defect in sitosterolemic patients is due 
to mutations in either one of the two ATP-binding cassette (ABC) transporters, ABCG5 and 
ABCG8 which are expressed in the intestins and liver. 
 
Bile acids binding resins like cholestyramine were firstly used in the treatment of sitosterolemia 
before ezetimibe was introduced. On the other hand HMG-CoA reductase inhibitors were 
effective in the treatment of hypercholesterolemia but not in the treatment of sitosterolemia. 
Ezetimibe was found to be effective in the treatment of hypercholesterolemia and also in the 
treatment of sitosterolemia (11,12). This drug is the first member of a new class of lipid lowering 
drugs known as cholesterol absorption inhibitors. It is suggesting  that ezetimibe acts throught the 
pathway contains NPC1L1 protein (16).  
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In the first study, oxycholesterols and oxyphytosterols were investigated in 13 patients with 
sitosterolemia before and after ezetimibe introduction, to see whether ezetimibe  has a significant 
effect on the serum levels of oxysterols. Two frequently used lipid emulsions were also analyzed 
for the presence of oxycholetserols and oxyphytosterols. In the second study, serum samples from 
31 sitosterolemic patients under different drug treatments (bile acids binding resins and statins)  
were anaylzed to see the effect of these drugs on the serum levels of cholesterol, lathosterol, plant 
sterols and plant stanols. 
For the first study GC-MS method was employed, where deuterium labelled for oxysterols were 
used as internal standard, whereas in the second study gas chromatography was used with  
5α-cholestane s internal standard. 
Ezetimibe did not produce any effect on the serum concentrations of oxycholesterols and 
oxyphytosterols as P values of t test were above 0.05 which was taken as a significance level. On 
the other hand, different oxycholesterols and oxyphytosterls were found in two frequently used 
lipid emulsions, as well as in the serum of 9 normal subjects.  
The lowest cholesterol serum level was found in the patients who treated with resins (136 mg/dl), 
where lathosterol serum level was increased with resins (0.535 mg/dl) and decreased with statins 
as a monotherapy (0.150 mg/dl) or a combined therapy with resins (0.078 mg/dl). 
Statistically, different drug treatment did not produce any significant effect on the serum levels of 
plant sterols and sitostanol, as the P values of ANOVA test were more than 0.05, but there was a 
significant difference in the serum level of campestanol between the patients treated with statins 
and those treated with resins.   
Oxidized forms of cholesterol and plant sterols are present in serum from normal subjects, 
sitosterolemic patients and two frequently used lipid mulsions, where eztimibe had no effect on 
their serum levels. It is still unknown whether oxyphytosterols affect health, as has been 
suggested for oxysterols, and that is why expanding our knowledge on circulating 
oxyphytosterols is of great importance. 
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